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Summary of thesis
Prostate cancer remains a major global health problem. Each year, in the UK, 
more than 27,000 patients are diagnosed with prostate cancer and approximately 
9,500 die of their disease. The therapeutic options range from treatments primarily 
aimed at cure, such as radical surgery or radical radiotherapy, in patients with organ- 
confined disease to palliative treatments such as hormone therapy or chemotherapy 
used in patients with advanced disease, hi chapter 1, the epidemiology, pathology, 
clinical features and treatment of prostate cancer are discussed.
In chapter 2, the specific cellular and non-specific systemic inflammatory 
responses are discussed. It is now recognised that disease progiession in cancer 
patients is not solely determined by the characteristics of the tumour, but also by the 
host response. Indeed, there is increasing evidence that both local and systemic 
inflammatory responses play an important role in disease progression in a variety of 
common solid tumours. Much of the initial work evaluating the role o f the 
inflammatory response in cancer patients was carried out in patients with colorectal 
cancel. In these patients, it has been shown that both the local cellular inflammatory 
response and the systemic inflammatory response are important detenninants of 
survival. The effects, however, of the local cellular and systemic inflammatory 
responses in patients with prostate cancer have not been established
The relationship between tumour bed lymphocyte infiltration and suivival in 
patients with prostate cancer is as yet poorly understood. To date there have been two 
studies conducted in this area of research; however, the results appear contradictory. 
Moreover, the relationship between infiltration by specific lymphocyte subsets and 
survival has not been assessed. In chapter three, the influence o f tumour-bed 
lymphocyte infiltration on survival in patients with prostate cancer was evaluated. It
VIII
was found that the presence of a prominent CD4+, but not CD8+, lymphocyte 
infiltrate in the tumour beds of patients with prostate cancer predicted poor survival, 
independent of stage. It has previously been suggested that this phenomenon may be 
explained by ineffective anti-tumoral immunity resulting from inactivation of 
lymphocytes in the tumour beds.
At presentation, there are a number of tumour-based factors which can predict 
suivival in patients with prostate cancer. Predicting suivival in the follow-up period 
is more difficult since PSA which is currently used for this purpose is normally 
suppressed by treatment. It is therefore of interest that the presence o f a systemic 
inflammatory response has been shown to be an independent predictor of suivival in 
patients with advanced gastrointestinal, lung and renal cancer. In chapter four, the 
effect of the systemic inflammatory response on outcome in patients with metastatic 
prostate cancer was investigated. It was found that the presence of a systemic 
inflammatory response, as evidenced by the presence of an elevated circulating C- 
reactive protein concentration predicted poor suivival, independent of PSA. If these 
preliminary results were to be confiimed in a larger study, it might provide a rational 
basis for therapeutic intervention with anti-inflammatory drugs. This is potentially of 
particular importance in patients with hormone refractory disease where there are 
currently few effective treatment options.
The basis of the systemic inflammatory response in patients with prostate 
cancer is not well understood. However, it has been shown that many factors, 
including IL-6, TNF-a, IL-1, leukaemia inhibitory factor and ciliary neurotrophic 
factor can potentially induce the systemic inflammatory response and the production 
of C-reactive protein. In chapter five, the relationship between IL-6 and C-reactive 
protein in patients with untreated prostate cancer and benign prostatic disease was
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evaluated. There was a close coiTelation between IL-6 and C-reactive protein both in 
patients with benign pro static disease and those with prostate cancer. This suggests 
that IL-6 is the main factor mediating C-reactive protein production in patients with 
both benign prostatic disease and prostate cancer. Furthennore, in patients with 
prostate cancer there was no significant correlation between PSA and IL-6 
concentrations. This observation suggests that in prostate cancer patients, the host 
may be responsible for production of IL-6 rather than the tumour itself.
Given that the inflammatory response appears to be important in predicting 
outcome in patients with prostate cancer, the question of whether C-reactive protein, 
could be used in the diagnostic setting to detect prostate cancer was explored in 
chapter 6. Although measurement of some PSA isoforms and their ratios could 
improve the specificity o f cancer detection when compared to the use of the 
conventional total PSA test, C-reactive protein was unable to reliably distinguish 
between patients with prostate cancer and those with benign disease.
In conclusion, these studies suggest that in patients with prostate cancer, both 
the presence of a systemic inflammatory response and a profuse CD4+ lymphocyte 
infiltration of the tumour bed, predict poor survival. The negative impact of the 
systemic inflammatory response has been well documented in a variety of other 
common solid tumours. In contrast, the effect on survival of tumour bed lymphocyte 
infiltration appears to differ between tumour types. Whereas the presence o f tumour- 
bed lymphocyte infiltration appears to be protective in patients with colorectal cancer, 
it appears to be detrimental in patients with prostate cancer. The reasons for these 
differences are as yet not clear. However, given that tumour lymphocyte infiltration 
parallels that of other inflammatory cells and that an elevated C-reactive protein is
X
associated with poor survival in both tumour types, it may be that the source of 
interleukin-6 differs in different tumours.
In colorectal cancer patients it has been reported that interleukin-6 
concentrations increase with tumour stage and coiTelate with CEA concentrations. 
This would suggest that in colorectal cancer patients, interleukin-6 is produced by the 
tumour cells. In contrast, in patients with prostate cancer there is no significant 
coiTelation between semm interleukin-6 and PSA concentrations. It may therefore be 
that in patients with prostate cancer, interleukin-6 is produced by the host 
inflammatory cells rather than the tumour. If  this were so, it might have implications 
for the treatment o f the systemic inflammatory response in patients with different 
tumour types.
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1.0 Introduction
Prostate cancer is the second commonest cause of cancer death in men in North 
America, Western Europe and the United Kingdom. In the United States, in 1998, 
more than 180,000 men developed prostate cancer and over 39,000 died of the disease 
(www.seer.cancer.gov). In the United Kingdom, in 2000, over 27,000 men developed 
prostate cancer and approximately 9,500 men died of their disease (www.crc.org.uk). 
In Scotland, over the same period, there were more than 1800 new cases detected and 
almost 800 deaths attributable to the disease. Incidence rates have been rising for 
many years and as a result the global health burden is increasing.
1.1 Incidence
The incidence of prostate cancer rises with age and varies significantly between 
different countries and ethnic groups.
Age
Prostate cancer is predominantly a disease of the elderly. For example. In Scotland, 
less than 0.5% of cases occur below the age of 50. The incidence rises rapidly with 
age, with 40% of cases occumng in patients over the age of seventy-five (ISD, 1998; 
Figure 1.1).
Figure 1.1; Prostate cancer and age at diagnosis in Scotland
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These age related trends have been confirmed by a series of autopsy studies, which 
showed that approximately 30% of men in their fifties and up to 70% of those over 
the age of eighty showed evidence of latent prostate cancer (Breslow et al, 
1977;Sheldon et al, 1980). Despite these findings, the life-time risk of developing 
clinically detectable prostate cancer up to the age of eighty is only 10%.
Geography
The incidence of prostate cancer varies seventy-fold between countries (SEER; Figure 
1.2). The United States has by far the highest incidence. The incidence rates are 
higher in Northern Europe than Southern Europe. Incidence rates in the Far East are 
low.
Global prostate cancer incidence
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Figure 1.2 (Data obtained from SEER)
Ethnic groups
There are also marked ethnic variations in incidence. For example, in the US, the 
incidence rates vary almost five-fold among different ethnic groups, African 
Americans having the highest rates and native Americans the lowest.
Trends
Analysis of incidence rates has shown interesting trends. For example, in the United 
States, there was a three-fold increase in the incidence rate between 1973 and 1992. 
Thereafter, incidence rates declined (Figure 1.3). By comparison, the Scottish 
incidence rates have been consistently lower.
Prostate cancer incidence in the US and Scotland
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Figure 1.3 (Data obtained from SEER and ISD)
It has been suggested that the apparent increases in the incidence rates, 
particularly in the US, may have been, in part, due to increased detection of small, 
non-lethal cancers, as a direct result of the introduction of PSA as a diagnostic tool, 
rather than a true increase in the incidence of the disease (ISD, 1998; Brewster et al, 
2000). Furthermore, in the US where screening is common, the high incidence 
reported may simply reflect the fact that more than 50% of white men over the age of 
50 years will have had PSA measured (Gann, 1997).
1.2 Mortality
Cancer o f the prostate is now the second commonest cause of cancer related death in 
men in the US (SEER), much of Europe and England and Wales (CRC). It is the third 
commonest cause of cancer related death in Scotland (CRC), (Figure 1.4).
Cancer deaths in Scotland
■ Lung
■ Large Bowel
■  Prostate
□ Stomach
□ Oesophagus
□ Others
Figure 1.4 (Data obtained from CRC cancer stats 2002)
Prostate cancer related mortality varies between countries. In general, increases in the 
mortality rates over the past two decades have not been as marked as the increases in 
incidence rates over the same time period (ISD, 1998). For example, in the US, 
despite a three-fold rise in incidence rates between 1973 and 1991, the mortality rates 
remained relatively stable. This provides further evidence to suggest that the high
incidence rates reported in some countries may be due to the detection of latent 
disease.
1.3 Survival
There is evidence to suggest that improvements in the treatment of patients with 
prostate cancer have led to a genuine prolongation of survival. For example, in the 
US, five-year survival rose from 67% in the mid 1970’s to 96% in the mid 1990’s 
(SEER). In Scotland, the five year survival rate increased from 37% to 50% over the 
same period of time (ISD, 1998; Figure 1.5).
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Figure 1.5 (Data obtained from SEER and ISD)
Clearly, survival rates in the UK appear to be lower than those in the United 
States. However, these apparent differences in survival must be interpreted with 
caution. These differences may in part be due to differences in case-mix, in particular 
the stage of disease at the time of diagnosis, variations in treatment or differences in 
the quality of registry-based data between countries.
A further possible source of bias is the variations in the use of prostate specific 
antigen (PSA) in different countries. The widespread use of PSA, either as a 
diagnostic test or as a screening tool, has led to an increase in the detection of small, 
localised tumours, most of which are unlikely to progress during the patients' lifetime. 
The inclusion of this additional cohort of patients may have contributed to the 
apparent increase in survival.
1.4 Aetiology of prostate cancer
In the West, prostate cancer is now one of the commonest malignancies to affect men. 
Despite the magnitude of the disease, little is known about the causes o f prostate 
cancer. However, there is information to suggest that both genetic and environmental 
factors have a role to play in the development of the disease.
1.4.1 Environmental factors in prostate cancer
There is good evidence that migrants who move from ai'eas of low incidence to areas 
with a higher incidence of prostate cancer acquire a higher risk of prostate cancer, 
often within one generation (Haenszel et al, 1968). For example, migrants fi-om Japan 
and China to the United States have higher rates of prostate cancer than their original 
ethnic population (King et al, 1963) (Shimizu et al, 1991). There is also some 
evidence to show that special population groups, such as the mormons, whose 
lifestyle habits distinguish them from the general population, have higher incidence 
rates for prostate cancer (Lyon et al, 1980). These two different obseiwations provide 
strong evidence that environmental factors contribute to the risk o f developing 
prostate cancer.
Age and sex-honnones
It has long been known that male hoimones (or androgens) such as testosterone, have 
an important role to play in the development and growth of the prostate gland. It is 
also thought that these androgens may also influence the development of prostate 
cancer (Kirby et al, 2000)
The precise role which androgens play in the development of prostate cancer 
is not fully understood. However, it appears that once established, the growth of 
prostate cancer may be partially dependant on androgen stimulation. It has been 
shown that prolonged administration of male sex honnones can also initiate prostate 
cancer gi'owth in experimental models (Kirby et al, 2000). Furthemiore, it has been 
noted that dihydrotestosterone (DHT) and testosterone levels are higher in neoplastic 
than benign prostate tissue (Habib et al, 1976). Despite this, serum levels of DHT and 
testosterone have not been coiTelated with the risk of developing prostate cancer 
(Ghanadian et al, 1979).
Dietary fat intake
High fat intake has been linked to an increased risk of developing prostate cancer in 
several studies (Rotkin, 1977; Schuman et al, 1977; Graham et al, 1983). Many 
mechanisms have been postulated to explain why high fat intake may encourage 
prostate tumour growth. These include modulaton of the inflammatory response, sex 
hormone metabolism, control of cell growth, apoptosis, lipid peroxidation and free 
radical formation (Pandian et al, 1999).
Vitamin A
It has been suggested by some studies that Vitamin A and its precursor beta-carotene 
may have a protective effect against prostate cancer (Rotkin 1977; Schuman et al, 
1977). The possible protective effect of Vitamin A is supported by the obsei-vations 
that Vitamin A and synthetic retinoids inhibit and reverse the carcinogen-induced 
hypeiplastic and anaplastic lesions in mouse prostate gland cultures (Chopra and 
Wilkoff, 1979).
Zinc, cadmium and selenium
A positive correlation has been established between estimated zinc and cadmium 
intake and mortality from prostate cancer. It has been suggested that zinc and 
cadmium may have this ^ affect by antagonism with selenium (Zaridze and Boyle, -tf 
1987), which appears to have a protective effect to many cancers including prostate 
cancer (Schi'auzer et al, 1977; Nomura et al, 2000; Brooks et al, 2001).
Vitamin D and calcium
It has been noted that prostate cancer seems to become more common in populations 
who live at increasing distances from the equator. Many have suggested that 
exposure to UV light and the production of vitamin D may, therefore, have a 
protective effect against the development of prostate cancer (Luscombe et al, 2001). 
This theory has been supported by the finding that a high calcium intake, nonnally 
associated with a high dairy food intake, is associated with a higher risk of developing 
prostate cancer (Chan et al, 1998). This observation may in part be explained by the 
theory that the high calcium intake, associated with a dairy diet, suppresses the 
production of vitamin D (Giovannucci, 1998).
Sexual activity
It has been suggested that sexual activity initiated early in life, multiple sexual 
partners and a history of sexually transmitted diseases (such as gonococcal infection) 
may increase the risk of subsequently developing prostate cancer. Others have, 
however, suggested that sexual activity may have little effect on the risk of 
developing the disease. One such study noted that 1400 reputedly celibate catholic 
priests had a similar incidence rate for prostate cancer as the rest of the male 
population (Ross et al, 1981),
Vasectomy
The relationship between vasectomy and risk of developing prostate cancer remains 
unproven. Some studies have suggested that a vasectomy almost doubled the risk of 
developing prostate cancer (Giovamiucci et al, 1993). Other larger studies have failed 
to demonstrate a link between vasectomy and prostate cancer (Sidney,I987).
Occupation
Prostate cancer is more likely to develop in men who live and work in the city than 
those who live in a rural environment (Blair and Fraumeni, 1978). Moreover, workers 
in the mbber, textile, chemical, phaiinacological, fertiliser and nuclear energy 
industries appear to be at particular risk. There is little evidence to conclusively 
identify any specific chemical agent. However, cadmium, tritium, and some isotopes 
of iron, cobalt, zinc and chromium have been suggested as candidates (Rooney et al, 
1993).
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Tobacco smoking and alcohol
Some studies have suggested a weak association between some types of smoking, 
such as cigar and pipe-smoking, and prostate cancer (Sharpe and Siemiatycki, 2001a 
). Overall however, a link between prostate cancer and smoking remains unproven 
(Lumey et al, 1997).
Most studies which have analysed the effect of alcohol consumption on the 
risk of developing prostate cancer have failed to demonstrate any convincing link 
(Breslow and Weed, 1998). However, it has been suggested that alcohol consumption 
at an early age (Shaipe and Siemiatycki, 2001b) or the consumption of spirits may be 
associated with increased risk (Sesso et al, 2001).
Non-steroidal anti-inflammatory drugs. (NSAlDs)
Non-steroidal anti-inflammatory dmgs reduce the production of prostaglandins by 
inhibiting the cyclooxygenase enzymes. In recent years there has been interest in 
whether NSAIDs have the ability to decrease the risk of, or prevent the progiession of 
human cancers. Indeed, there is evidence to suggest that NSAIDs can directly inliibit 
tumour growth in prostate cancer cell lines (Pollard and Luckert, 1986). Furthermore, 
there is gi'owing evidence that regular consumption of NSAIDs reduces the risk of 
developing prostate cancer (Nomsh et al, 1998; Roberts et al, 2002).
The use of anti-inflammatory dmgs is not, however, without its hazards. Non- 
selective NSAIDs such as aspirin, indomethacin or ibuprofen which inliibit both the 
COX-1 and COX-2 enzymes are well known to cause platelet dysfunction, gastric 
ulceration and renal impairment (Hemy DA, 1998). These side-effects are thought to 
be largely due to the COX-1 inhibitory effects. The development of selective COX-2 
inhibitors or “coxibs” promised to provide effective anti-inflammatory action with a 
reduced side-effect profile. Unfortunately, however, it is now recognised that
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although the coxibs do provide a lower risk of gastric ulceration, their use causes an 
increase in the risk of cardiovascular events such as mycocardial infarction. This has 
consequently led to a reduction in the use of coxibs.
1.4.2 Hereditary aspects of prostate cancer
Clinical studies have provided evidence of familial clustering in around 20% of 
prostate cancer cases (Aprikian et al, 1995; Keetch et al, 1995). However, only 
around 9% of cases are considered to be true hereditary cancers (Carter et al, 1992; 
Bastacky et al, 1995).
The earliest evidence for a genetic predisposition in prostate cancer came from 
studies which examined Mormons in Salt Lake City (Woolf et al, 1960). It was noted 
that prostate cancer appeared in clusters around specific families. Furthermore, 
Steinberg and his colleagues (1990) reported that first-degree relatives of patients 
with prostate cancer were almost twice as likely to develop the disease as the nonnal 
population. Furthennore, a subsequent study showed that men with two or three 
affected first- degi'ee relatives had a 5 and 11-fold increase respectively, in the 
lifetime risk of developing the disease (Gronberg et al, 1996).
Moreover, data from a Swedish twin study has provided more convincing 
evidence to support the theory of genetic predisposition to prostate cancer (Gronberg 
et al, 1994). This study compared heterozygotic twins with their monozygotic 
counterparts. It was found that a monozygotic twin whose brother had developed 
prostate cancer was five times more likely to develop the disease than a brother of an 
affected heterozygotic twin (Gronberg et al, 1994).
The genetic basis for these observations is not clear. However, it is thought 
that many types of tumour may be initiated by specific genetic changes, which may be
12
inlierited or occur spontaneously. In particular, it is known that alterations may occur 
in a group of quiescent genes called proto-oncogenes which convert them to active 
oncogenes. These oncogenes, once activated, are thought to initiate malignant change 
and promote tumour growth. Alternatively, tumour-suppressor genes, which normally 
act to inliibit tumour giowth, may be “switched o ff’.
The concept that there may be genetic factors which predispose to cancer in 
some patients has been reinforced by the discovery of specific gene mutations which 
have been associated with increased susceptibility to certain cancers, for example the 
BRCAl gene in breast cancer (Lee and Boyer, 2001), and the ARC gene in colorectal 
cancer (Su et al, 2000). It is therefore of interest that two highly penetrant genes 
which predispose to breast cancer (BRCAl and BRCA2) also confer an increased risk 
of developing prostate cancer of 3 and 7 fold respectively (Gayther et al, 2000).
Furthermore, a major susceptibility locus for prostate cancer, the “Human 
Prostate Cancer Gene 1” has recently been identified on chi'omosome 1,24. This gene 
locus has been implicated in around 30% of the hereditary prostate cancers in one 
study (Smith et al, 1996).
1.5 Anatomy of the prostate
The name “prostate” is thought to have been derived from the Greek word 
“prohistani”, which means to stand in front of, and was used to describe the 
anatomical relation of the prostate gland to the urinary bladder (Kirby et al, 2000).
The anatomy of the prostate gland is of importance when considering the 
distribution of benign and malignant disease to affect the gland. Furthermore, a clear 
understanding of the anatomy of the pelvis is essential when undertaking prostate 
surgery.
13
Gross Anatomy of the prostate gland
The prostate gland consists of right and left lateral lobes, which merge in front of the 
urethra. The middle lobe lies above the lateral lobes; enlargement of this lobe rapidly 
leads to urethial obstmction. The sphincter uretlii'ae lies immediately beyond the 
prostate gland. Therefore, damage to the sphincter muscle fibres during prostate 
surgery can result in post operative urinary incontinence.
Important neurovascular bundles lying dorsolaterally to the prostate carry 
neiwe fibres and blood to the corpora cavernosa of the penis, and are critical to the 
development of the normal erectile responses. Their division in the original radical 
prostatectomy procedure inevitably resulted in impotence. The observation that these 
neurovascular bundles lay outside the Demiovilliers fascial layer led to the 
development of the nerve spaiing radical retropubic prostatectomy. This technique 
appears to be associated with a reduced incidence of post-operative impotence.
Zonal anatomy of the prostate gland
In 1968, McNeal described three distinct anatomical regions, namely the peripheral, 
transitional and central zones. The peripheral zone comprises almost 65% of the 
glandular volume. The central zone, comprises around 25% of the prostate volume. 
The smallest of these areas is the transitional zone. The distinctions between these 
areas are usually difficult to perceive, because, in the absence of disease, their 
anatomical boundaries are relatively subtle.
The clinical significance of the zonal anatomy of the prostate is in 
understanding which areas of the gland are susceptible to benign and malignant 
disease. Benign prostatic hypertrophy affects the transitional zone and frequently 
distorts and compresses the adjacent peripheral zone. In contrast, prostate cancer can
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affect any zone of the gland, but is most commonly found to affect the peripheral
zone.
1.6 Pathology of the prostate gland
Prostate cancer usually arises from tissue on the posterior aspect and the periphery of 
the gland (Quinn et al, 1990). Since both prostate cancer and benign prostatic 
hypertrophy are common histological findings, they are often found to co-exist.
The vast majority of prostate cancers are adenocarcinomas which arise from 
the epithelial lining of the secretory acini. Prostate cancer spreads within the gland, 
sometimes causing uretliral obstruction. However, because it most frequently arises 
from the periphery of the gland, it has often spread locally to the adjacent structures or 
metastasised before urinary symptoms develop. Metastatic spread may be via the 
lymphatic system to the pre-sacral, iliac and para-aortic lymph nodes or blood borne 
to the skeleton, leading to the foimation of characteristic osteosclerotic bone lesions 
(Muirs Textbook of Pathology, 1992).
Prostatic glandular tissues, including primary prostate adenocarcinomas and 
metastatic lesions, produce acid-phosphatase and prostate specific antigen (PSA). 
Specific antibodies to these markers can be used to confirm that metastatic deposits of 
adenocarcinoma originate fr'om the prostate gland.
Wherever possible, cytological or histological conftnnation of a diagnosis 
should be sought in any patient where there is a clinical suspicion of cancer. In the 
United Kingdom and the United States, most suspected cancers are confirmed by the 
use of spring-loaded devices, which can be used to take multiple core biopsies, often 
under ultrasound guidance.
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Latent prostate cancer
Prostate cancer is unique among potentially lethal human cancers in that a wide 
discrepancy exists between the incidence of histologically-confiimed cancer and 
clinical disease.
In 1956, Franks reported that a high proportion of men examined at autopsy 
had microscopic foci of prostatic adenocarcinoma. These small tumours were found 
to affect around 30% of men over fifty years of age. Subsequent post-mortem studies 
have demonstrated a surprisingly high incidence of histologically proven prostate 
cancer in younger men. For example, in one study, Saki" and co-workers (1993) found 
small foci of prostate adenocarcinoma in 25-30% of men aged between 30 and 39 
years of age.
Breslow and co-workers (1977) examined the geogi apliical distribution of 
autopsy-detected prostate cancer. They reported that the incidence of small prostate 
tumours was similar in all seven countries studied, and that the incidence of these 
small tumour foci did not increase with age. However, the incidence o f larger 
tumours detected at autopsy reflected the incidence of clinical disease in the local 
populations. Furthennore, the incidence of these larger lesions was found to increase 
with age and varied between ethnic population gi'oups.
Scardino (1989) attempted to estimate the extent of the discrepancy between 
the high prevalence of the disease at autopsy and the low incidence of clinical disease. 
In 1985, in the United States, 86,000 men were diagnosed with prostate cancer and 
25,500 men died of the disease. However, infonnation from previous autopsy studies 
suggests that in the same year, over 8 million men would have harboured undiagnosed 
prostate cancer. Thus Scardino estimated that only 1 in 95 men with cancer were 
diagnosed with the disease, and only 1 in 323 men with prostate cancer died of the
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disease. Clearly this suggests that the majority of small prostatic tumours, which can 
be detected at autopsy, do not progi'ess to clinical prostate disease.
The term “latent prostate cancer” has been used to describe this phenomenon. 
It is thought that many of these small, well differentiated prostate cancers lack the 
ability to gi'ow, de-differentiate and metastasise within a patients lifetime. 
Furthermore, it is known that prostate cancer cells grow slowly. Indeed, prostate 
cancers have been shown to have cell-doubling times of around two years (Stamey 
and Kabalin, 1989).
The biological significance of “latent carcinoma” remains unclear but it is 
Icnown that many small prostate cancers are of little clinical importance. However, 
there is evidence that the increasing use o f diagnostic tests, such as PSA, to detect 
prostate cancer is increasing the number o f men diagnosed with “latent” disease. 
Unfortunately, there is no definitive method of identifying which o f those lesions will 
progress to clinical disease and which are likely to remain quiescent over the patient’s 
lifetime. Potentially, treatment of these latent cancers could result in inappropriate 
and unnecessary patient morbidity.
Premalignant change in the prostate gland
hi 1986, McNeal and Bostwick identified the existence of dysplastic prostatic lesions 
which they called “intraductal dysplasia”. It was noted that these lesions exhibited 
many features, including cytological atypia and nuclear polymorphism, which are 
associated with other premalignant conditions. In 1989, following a consensus 
meeting, intraductal dysplasia was renamed prostatic intraepithélial neoplasia or PIN. 
This brought the nomenclature into line with other pre malignant conditions such as 
CIN (cervical intraepithélial neoplasia).
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The clinical implications of prostatic intraepithélial neoplasia are 
controversial. The presence of PIN has been shown to occur approximately a decade 
before the onset of prostate cancer (Sakr et al, 1996). Ai'eas of PIN have been shown 
to be closely associated with foci of prostate cancer. Furthermore, the distribution of 
clinically relevant prostate cancer and PIN is similar (Quinn et al, 1990). It has also 
been shown that patients who possess widespread dysplastic change within their 
prostates are more likely to develop multi-focal malignancy (Quinn et al, 1990). This 
close coiTelation between PIN and malignancy therefore suggests that the two 
conditions are linked.
Pathological prognostic factors.
Many prognostic factors have been evaluated in prostate cancer; few have been shown 
to be of proven clinical value. A recent consensus conference organised by the 
College of American Pathologists (Bostwick et al, 2000) divided factors into three 
categories reflecting the strength of published evidence. Factors were ranked as: 
Category I, factors of proven prognostic importance, useful in clinical practice; 
Category II, factors that have been extensively studied but whose importance remains 
to be validated in statistically robust studies; and Category III, all other factors not 
sufficiently studied to demonstrate their prognostic value.
Category I prognostic factors include pre-operative serum PSA antigen level, 
TNM stage, histological grade and surgical margin status. The most commonly used 
grading system is that devised by Gleason (1977). Areas within the tumour were 
scored 1 to 5 according to the degree of dysplasia, the more dysplastic lesions being 
given higher scores. A “Gleason score” is calculated using combined scores of the 
two most prominent areas. This score was shown to provide important prognostic 
infonnation and also to be readily reproducible (Gleason, 1992).
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Category II factors include tumour volume, histological type and DNA ploidy. 
For example, tumour volume has been shown to correlate with tumour gi’ade, larger 
volume tumours tending to be of higher gi ade than smaller prostate cancers (McNeal 
and Bostwick, 1986). Tumour volume has also been shown to relate to the frequency 
of capsular penetration and seminal vesicle invasion (McNeal et al, 1986).
Category III factors include perineural invasion, neuroendocrine 
differentiation, microvessel density, proliferation markers and oncogenes such as c- 
myc, c-erb-B2 and bcl-2. For example, angiogenesis, as evidenced by micro-vessel 
density, is thought by some to play an important role in tumour progression and 
metastasis (Halvorsen et al, 2000).
1.7 Clinical presentation
Over the past decade the pattern of presentation of patients with prostate cancer has 
changed dramatically. Historically, a relatively high proportion of men presented 
with locally advanced or metastatic disease. However, the introduction of more 
sensitive diagnostic tools such as trans-rectal ultrasound guided biopsy of the prostate 
has led to an increase in the numbers of men being diagnosed with early stage disease. 
For example, in the US, the number of patients presenting with localized prostate 
cancer more than doubled fr om 50 cases per 100,000 in 1985, to 110 cases per
100,000 of population in 1995 (SEER). During the same period, the number of newly 
diagnosed patients with métastasés fell by 56%, from 14.9 to 6,6 cases per 100,000 
head of population. As a result, there has been a marked shift in the pattern of clinical 
presentation at diagnosis.
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1.7.1 Symptoms associated with prostate cancer
At diagnosis, most men with localised prostate cancer are asymptomatic. Although 
symptoms do occur in association with prostate cancer, they nonnally result from 
bladder outflow obstruction, local invasion by the tumour or metastatic disease.
Symptoms caused by bladder outflow obstruction are generally divided into 
irritative and obstructive symptoms. Irritative symptoms result from instability of the 
detmsor muscle of the bladder, secondary to obstruction, and include urgency and 
frequency. Obstructive symptoms result as a consequence of the mechanical 
obstmction of the uretln a and include hesitancy, reduced urinary flow and incomplete 
bladder emptying. In extreme outflow obstruction, patients can develop a urinary 
retention, which requires urgent decompression.
In the US, 6% of men with prostate cancer have evidence of distant métastasés 
at the time of their diagnosis (SEER). In the UK, the proportion is traditionally much 
higher. The spine is the commonest site of bone métastasés (Gonzales et al, 1991). It 
is thought that blood draining fr om the prostate gland through the valve-less vertebral 
venous plexus may allow prostate cancer cells to metastasise directly to the lumbar 
vertebrae (Batson, 1940). In addition to the lumbar spine, prostate cancer métastasés 
commonly affect other bones including the ribs, pelvis, sternum, humerus, neck of 
femur and skull. Bone métastasés can produce a variety of complications including 
pain, pathological fracture, spinal cord compression and man'ow failure.
1.7.2 Clinical examination
Examination of the prostate gland is facilitated by a digital rectal examination (DRE). 
This examination allows the clinician to assess the posterior surface of the prostate 
gland. Particular attention is paid to the size and symmetry of the gland, the
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preservation of the median sulcus and the presence of any palpable prostatic nodules. 
Destruction of the median sulcus of the prostate or the presence o f palpable nodules is 
suggestive of prostate cancer. DRE is also used to define the extent of local disease.
1.7.3 Prostate Specific Antigen
Prostate Specific Antigen (PSA) is a 28,400 Dalton glycoprotein comprising 237 
amino acid residues and a oligosaccharide side chain. PSA is synthesised by the 
ductal and acinar epithelium of the prostate gland. It is secreted in the seminal fluid 
and acts to liquefy the seminal coagulum, thus releasing the entrapped sperm. The 
basement membrane of the prostatic epithelium normally creates a barrier preventing 
the escape of PSA into the circulation. Dismption of the basement membranes by 
disease allows PSA to enter the systemic circulation. The predominant molecular 
foim present in the plasma is a complex of PSA and alpha 1-antichymotrypsin. Free 
PSA represents a small but variable proportion of the total PSA. Many disease 
processes within the prostate gland including benign prostatic hypertrophy, infection 
and inflammation are associated with elevated circulating PSA concentrations.
PSA and benign pro static hypertrophy
Benign prostatic hypertrophy (BPH) is one of the commonest ailments affecting aging 
men, with more than 60% of men in their sixties having histological evidence of the 
disease. BPH leads to an increase in prostatic size and subsequently an increase in the 
circulating PSA concentrations. It has been estimated that for every gram of prostate 
tissue present there is an increase in circulating PSA concentrations of 0.3micrograms 
per litre (Stamey et al, 1987).
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PSA and inflammation of the prostate
Inflammation of the prostate gland can be acute or cluonic, bacterial or sterile. Acute 
infection within the prostate commonly produces a short-lived elevation in the 
concentrations of circulating PSA. In contrast, clrronic prostatitis only produces an 
elevation in circulating PSA concentrations in around ten percent of patients 
(Pansadoro et al, 1996). Other non-infective causes of prostatic inflammation 
including urethral catheterisation, prostatic biopsy, digital rectal examination and 
acute urinary retention have also been shown to produce an increase in circulating 
PSA concentrations (Crawford et al, 1992).
PSA and Pro static Intraepithélial Neoplasia
Prostatic Intraepithélial Neoplasia (PIN) is characterised by cytologically atypical 
cells lining architecturally normal ducts. As PIN does not lead to basement 
membrane disruption, serum PSA concentrations are unaffected.
PSA and prostate cancer
The rapid rise in the use of prostate specific antigen is a result of its close association 
with prostate cancer. The growth of prostate cancer within a gland leads to the 
disruption of the basement membranes and subsequently to leakage of PSA into the 
circulation. However, as discussed earlier, prostate cancer is not the sole cause of 
increased circulating concentrations of PSA.
Since the introduction of PSA, the mode of presentation of prostate cancer has 
changed markedly (Murphy et al, 1999). Prior to the introduction o f PSA, nearly all 
prostate cancers presented at an advanced stage with either bladder outflow 
obstruction or skeletal métastasés. In contrast, around one third of men cun ently
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diagnosed with prostate cancer in the UK present with only a raised PSA (Milford 
Ward et al, 2001).
One of the problems with the use of PSA cuiTently is the lack of an 
international standard. At present different assays may produce widely varying 
results from the same serum sample. The scale of this problem is put in proportion 
when it is considered that in Europe alone there are currently around eighty different 
PSA assays available. This causes difficulties in compiling reference ranges for 
benign and malignant disease. PSA values obtained using different assays are 
therefore not directly comparable. Furthermore, many manufacturers have not 
established normal control values for their assay.
Reference ranges o f PSA
The most commonly quoted upper limit o f “noiTnal” was established using the 
original Hybritech PSA assay. Almost 500 men with no history o f prostate disease 
were involved in the study. When circulating PSA concentrations were measured, 4 
micro-grams per litre represented the 99^ ’’ centile in the study population (Myrtle et al, 
1986). Many clinicians therefore commonly use this value as an upper reference 
limit. However, in more recent studies approximately 18-25% of men found to have 
prostate cancer had semin PSA concentrations below this value (Kirby et al, 2000). 
Furthennore, around two thirds o f men who have semm PSA values greater than 4 
micro-gi'ams per litre will have benign histology on initial prostate biopsy (Kirby et 
al, 2000).
This lack of specificity has led to the development of several methods of 
interpreting PSA with the aim of improving specificity without a significant reducing 
sensitivity. These include age specific reference ranges, PSA density and PSA 
velocity.
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Age specific PSA reference ranges
It is known that circulating PSA concentrations rise with age. Age specific ranges 
were introduced as a stratagem to improve sensitivity in the older age groups, whilst 
presei-ving sensitivity in younger men. In practice, this means lowering the PSA 
tlneshold for investigation in younger patients. In older patients, the PSA threshold is 
often raised above the standard cut-off level of 4ng/mL to reduce unnecessary 
biopsies.
PSA Density
This technique relates circulating PSA concentration to glandular volume. It is 
thought that in some cases this may help separate large benign glands from malignant 
prostates.
PSA velocity
Another approach to improving assay specificity is PSA velocity. This approach 
measures the rate of change in circulating PSA concentrations over a given period of 
time. The measurement of PSA doubling times is similar. It is thought that the rate of 
change in PSA concentrations in patients with malignancy is greater than in those 
with benign disease. At present there is no clear evidence that PSA velocity or 
doubling times are superior to conventional PSA measurements in the diagnosis of 
prostate cancer (Perrin, 2006). However, recent studies have indicated that a PSA 
velocity of >2ng/mL/year is an important predictor of poor outcome in patients being 
treated with radical surgery (D’Amico et al, 2004) or radiotherapy (D’Amico et al, 
2005).
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PSA and stage of disease in prostate cancer
Serum PSA concentrations are also useful in distinguishing patients with localised 
disease from those who have metastatic disease at presentation. Oesteling et al (1993) 
showed that of approximately 300 men with a circulating PSA concentration of less 
than 20 micro-grams per litre, only one patient had evidence of skeletal métastasés. 
Other gi'oups have reported similar findings (Lee et al, 2000). The reliability 
demonstrated by PSA combined with the high cost of nuclear imaging has led some 
authorities to advise bone scaninng only in those patients with PSA concentrations 
above 10 micrograms per litre.
1.7.4 Bionsv of the prostate gland.
Once abnormal biochemistry or suspicious findings on digital rectal examination have 
raised the suspicion of prostate cancer, the clinician will normally seek pathological 
confirmation of malignancy. Historically, prostatic biopsy to obtain a tissue diagnosis 
of cancer was performed blind. However, the advent of ultrasound teclmology 
offered a new way to evaluate the prostate, and biopsy techniques were adapted to 
incorporate ultrasound guidance.
Transrectal ultrasound and biopsy.
Transrectal ultrasound (TRUS) was first used to evaluate the prostate in the 1960's 
(Takahashi and Ouchi, 1963). However, the images obtained at that time were of 
poor quality. As ultrasound technology has become more sophisticated, the use of 
TRUS in the evaluation of prostate disease increased. By the mid 1980's, use of the 7 
MHz ultrasound probe, which more clearly delineated the architecture of the prostate, 
had become an established diagnostic approach.
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TRUS has tlii'ee primary roles in the assessment of prostate disease. Firstly an 
estimate of the prostate volume can be made, secondly, abnonnal areas of the gland 
can be targeted for biopsy and thirdly, the anatomy of prostate can be visualised 
allowing systematic biopsies of ultrasonically “noimal” tissue to be taken.
Estimation of the prostate volume.
As circulating PSA concentrations are partially determined by the volume of prostate 
tissue within the gland, it is useful for the clinician to have an estimate of the size of 
the gland (Drawer and Chetner, 1997). The importance of prostate volume is apparent 
when considering the concept of PSA density. This method of interpreting PSA 
should offer a way of differentiating between those patients who have a raised PSA as 
a consequence of large glandular size, and those patients whose glands are producing 
an excess of PSA in proportion to their size. In theory, patients in the second gioup 
should be at higher risk of harbouring prostate cancer.
The use of TRUS to target suspicious lesions within the prostate gland.
Areas of the gland are said to be hyperechoic, isoechoic or hypoechoic depending on 
whether the ultrasound image produced is lighter, similar to, or darker than the image 
generated by nonnal peripheral zone tissue. Cancer of the prostate was initially 
thought to have a hyperechoic appearance on ultrasound; however, more recent 
studies have shown that the most common ultrasound finding in prostate cancer is a 
hypoechoic peripheral zone lesion (Lee et al, 1986).
However, TRUS is not without its weaknesses. For example, hypoechogenic 
images within the prostate gland may also occur in other diseases such as prostatitis, 
prostatic infarction, scaning of the gland and prostatic intraepithélial neoplasia 
(Langer, 1999). Furthermore, up to 40% of prostate cancers are isoechoic and
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therefore “invisible” to TRUS. This number may be even higher today as more 
patients present with early stage disease.
The limitations in the sensitivity and specificity of TRUS as a method of 
identifying malignant lesions has led to the exploration of novel ultrasound 
teclmiques, such as the use of intravenous microbubble ultrasound contrast agents 
(Frauscher et al, 2001).
Systematic TRUS-guided biopsy of the prostate
In the PSA era patients are presenting with earlier disease, when tumours are more 
commonly non-palpable and isoechoic. An important function of TRUS has become 
the ability to demonstrate the anatomy of the prostate and therefore facilitate 
systematic tissue sampling from all relevant areas of the gland, even when the 
ultrasound image generated by that tissue is nonnal. In 1989, Hodge and co-workers 
demonstrated that cancer detection rates could be greatly improved if systematic 
sextant biopsies of sonogiaphically “normal” prostate tissue were taken.
1.8 Staging of Prostate cancer
The aim of staging is to define the extent of the disease process. The first clinical 
classification system widely used in the assessment of prostate cancer stage was 
introduced by Whitmore in 1956, and later updated by Jewett in 1975. These 
classification systems have now largely been replaced by the TNM system of staging 
(see Table 1.1). The TNM classification breaks tumour stage into tln*ee components; 
the T component which reflects the extent of disease at the primary site, the N 
component which reflects the presence or absence of nodal métastasés and the M 
component which indicates the presence or absence of distant tumour métastasés. 
This method of classification became established internationally in the early 1990's
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and was updated in 1997. The 1997 revision resulted in changes to the original 
system, including the amalgamation of the T2a and T2b stage groups and 
reassigmnent of T2c tumours as T2b cancers. In addition, the distinction between T3a 
and T3b tumours has been abandoned and T3c tumours are now assigned to the T3b 
category (Hoedemaeker et al, 2000).
Table 1.1- A comparison of the TNM and Whitmore-Jewett staging classifications
TNM
(1992)
Whitmore-
Jewett
Description of stage
Tx Tumour can not be assessed
TO No evidence of tumour
T la Al Tumour an incidental finding at TURP (<5% of tissue involved)
Tib A2 Tumour an incidental finding at TURP (>5% of tissue involved)
T ic BO Non palpable tumour, identified by raised PSA
T2a B1 Tumour involves half a lobe or less
T2b B1 Tumour involves more than half a lobe but not both lobes
T2c B2 Tumour involves both lobes
T3a Cl Unilateral extra capsular tumour extension
T3b Cl Bilateral extra capsular tumour extension
T3c C2 Tumour invading seminal vesicles
T4a Tumour invades bladder, external sphincter or rectum
T4b Tumour invades levator muscles or is fixed to pelvic side wall
1.8.1 The clinical assessment o f local tumour extent.
The Digital Rectal Examination.
Accurate assessment of local tumour extent is particularly important in patients who 
are being considered for radical treatment. The traditional method of evaluating the 
local extent of prostate cancer is based on digital rectal examination (DRE). If an area
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of abnormality, suggestive o f prostate cancer, is found the extent of disease (T-stage) 
can be defined on the basis of the criteria outlined in Table 1.1.
Whilst there is some correlation between DRE and final pathological stage, 
this method of assessing local tumour extent has its limitations. In addition to being 
subject to clinical experience and inter-observer enor, the DRE frequently 
underestimates the extent of disease (Ohori et al, 1994). For example, it has been 
shown in patients undergoing radical prostatectomy that only 41% of patients 
predicted to have T2b cancers and only 35% of patients predicted to have T2c prostate 
cancers had organ confined disease (Partin et al, 1993).
Transrectal ultrasound.
Transrectal ultrasound (TRUS) is the commonest modality used to image the prostate 
gland. Some cancers have variable echo characteristics, on ultrasound, which can be 
used to predict tumour extension through the capsule or into the seminal vesicles.
The criteria for extracapsular extension include bulging or discontinuity of the 
boundary echo. Seminal vesicle invasion is suggested by fullness and loss of the 
normal tapering of the gland at the prostate base (Wilkinson and Hamdy, 2001). 
Unfortunately, recognising these subtle findings appears to be largely operator- 
dependant and this has led to variations in the accuracy of TRUS as a staging 
modality (Hardeman et al, 1989; Rifkin et al, 1991).
More recently two large trials have suggested that TRUS does not perform 
better than the digital rectal examination as a staging modality for predicting organ 
confined prostate cancer (Smith et al, 1997; Liebross et al, 1999). The authors 
concluded that DRE provided prognostic information at least equivalent to TRUS and 
was preferable because o f its low cost.
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Magnetic Resonance Imaging (MRI)
On MRI, extra-capsular prostate cancer extension is suggested by asymmetry of the 
neurovascular bundle, obliteration of the retroprostatic angle, asymmetry of the 
seminal vesicles and loss o f the nonnal fat plane between the base of the prostate and 
the inferior aspect of the seminal vesicles (Wilkinson and Hamdy, 2001). Rifldn and 
co-workers (1991) assessed the ability of MRI to predict final pathological stage in 
patients with prostate cancer and found that MRI coirectly staged 77% of cases with 
advanced disease and 57% of patients with localised prostate cancer
1.8.2 The assessment of Ivmnh node status.
Historically, around 20% of patients undergoing radical prostatectomy had lymph 
node métastasés at the time of surgery. More recently, improvements in nodal staging 
and better patient selection has meant that only 2-3% of patients undergoing radical 
prostate surgery have lymph node métastasés (Kirby et al, 2000).
Since the techniques for screening potential surgical candidates for lymph 
node métastasés are time-consuming, expensive and not always reliable, it is 
generally accepted that only those patients thought to be at high risk of having nodal 
disease should be investigated. For example, it has been reported that patients with 
high-giade tumours (Gleasons score 8+) and with circulating PSA concentrations 
greater than 20 are at high risk of having lymph node métastasés (Partin et al, 1993) 
and therefore warrant investigation.
Computed tomography (CT).
The diagnosis of lymph node métastasés by CT is based solely on the detection of 
lymphadenopathy. Any lymph node found to be larger than 1cm is considered to be 
abnonnal (Wilkinson and Hamdy, 2001). However, although the reported specificity
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of CT in detecting lymph node métastasés is high, the sensitivity is low (Rorvik et al, 
1998). The low sensitivity levels reported probably reflect the fact that most lymph 
node métastasés are microscopic and do not therefore result in detectable lymph node 
enlargement.
Magnetic Resonance Imaging (MRI)
MRI has an advantage over CT in that it can be used to assess lymph node status at 
the same time as assessing the prostate gland itself. However, the sensitivity and 
specificity reported for the detection of lymph node métastasés using MRI varies 
widely between studies (Wolf et al, 1995; Jager et al, 1996). The low detection rates 
limit the usefulness of CT and MRI in assessing lymph node status prior to radical 
therapy.
Staging lymphadenectomy
Lymph nodes infiltrated with prostate cancer are often not enlarged, and as a result 
non-invasive radiological imaging has often proven to be unreliable as a method of 
assessing lymph node status. Pelvic lymphadenectomy remains the “gold standard” 
method of obtaining a histopathological diagnosis of lymph node métastasés.
Lymphadenectomy is not usually directed at all patients in whom radical 
treatment is being considered, but instead is targeted at groups of patients thought to 
be at high risk of having lymph node métastasés. Lymphadenectomy can be earned 
out laparoscopically or as an open procedure before radical therapy or at the time of 
prostatectomy. High specificities, accuracies and predictive values are reported in 
patients undergoing staging lymphadenectomy (Alagiri et al, 1997).
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1.8.3 The assessment of distant metastatic spread.
Prostate cancer most commonly spreads to the well vascularised areas of the skeleton, 
including the spine, ribs, skull and the proximal ends of the long bones. These 
métastasés may cause bone pain, hypercalcaemia and pathological fractures. 
Infiltration of the bone man ow can cause marrow suppression and leukopenia. Less 
commonly, metastatic sites in the vertebral column can result in the impingement of 
nei-ve roots or the spinal cord giving rise to nerve root compression syndromes or 
spinal cord compression.
Historically, 30-35% of patients newly diagnosed with prostate cancer in the 
USA had evidence of bone métastasés at presentation (Lee and Oesterling, 1997). 
Today, as a result o f improved and earlier detection, the proportion of men presenting 
with advanced prostate cancer is much smaller. For example, it has been estimated 
that approximately 8% of white Americans now have metastatic disease at the time of 
presentation (Landis et al, 1999). However, a large proportion o f patients will 
develop bone métastasés despite attempts at curative therapy. Indeed, 85-100% of 
patients who die of prostate cancer have bone involvement (Carlin and Andriole, 
2000).
The detection and monitoring of bone métastasés is therefore important for a 
number of reasons. Firstly, the detection of bone métastasés makes any use of radical 
therapy inappropriate. Secondly, it alerts the clinician to the possible complications 
of metastatic disease such as pathological fracture, pain or cord compression and 
allows the clinician to initiate appropriate therapy quickly. Finally, the detection of 
bone métastasés has important prognostic implications for the patient.
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Radionucleotide bone scanning
The most sensitive and widely used method of detecting osseous métastasés in 
patients with prostate cancer is teclmetium 99m bone scanning. Although false 
negative results occur in less than 1% of cases, false positive results are more 
common. For example, hot spots may reflect a spectrum of benign disease including 
Pagets disease, trauma and degenerative bone disease as well as metastatic bone 
deposits (Kirby et al, 2000).
Traditionally, a high proportion of patients newly diagnosed with prostate 
cancer undei*went bone scanning at diagnosis. More recently, several authors have 
been successful in identifying groups of patients at low risk of having bone métastasés 
in whom bone scanning may not be indicated. Several groups have examined the 
relationship between PSA at diagnosis and the risk of having a positive bone scan 
Gleave et al, 1996). For example, Kosuda and co-workers (2002) reported that only 
1% of patients with PSA concentrations less than lOng/ml had a positive bone scan. 
Both these authors conclude that it was possible to omit base-line bone-scans in 
patients with serum PSA concentrations less than 1 Ong/ml.
Guidelines hom  the National Comprehensive Cancer network recommend a 
bone scan in those patients who have T1 or T2 disease only if there serum PSA 
concentrations are greater than 1 Ong/ml or whose Gleasons score is eight or above. It 
is also recommended that all patients who are symptomatic or who have T3 or T4 
disease undergo bone scanning (Baker et al, 1996).
Plain film X-ray
The majority of bone métastasés from prostate cancer are osteosclerotic. Plain film 
X-rays have low sensitivity levels for the detection of bone métastasés, since a 50% 
change in bone density must occur before metastatic lesions can be detected on plain
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film. Ill contrast, the high specificity for the detection of bone métastasés associated 
with plain film X-ray makes them of use in differentiating between benign and 
malignant disease in patients with equivocal bone scans (Carlin and Andiole, 2000).
Magnetic Resonance Scamiiiig (MRI).
It has been suggested that MRI might offer an alternative to bone scanning as a 
screening tool for bone métastasés in prostate cancer patients. For example, Venz and 
co-workers (1994) demonstrated increased sensitivity and specificity for the detection 
of bone métastasés using MRI when compared to routine bone scans. The main 
advantage of MRI was an increased ability to discriminate between benign and 
malignant bone disease.
Markers of bone turnover.
Alkaline phosphatase, one of the older biochemical tools used for the investigation of 
metastatic bone disease, remains a reliable and widely used marker of osteoblastic 
activity. In one recent study examining the relationship between bone scan results 
and semm PSA and alkaline phosphatase concentrations, the authors concluded that 
alkaline phosphatase concentrations correlated better with the outcome of the bone 
scans than did PSA (Wymenga et al, 2001).
Prostate specific antigen (PSA) and stage
Previous studied have shown that there is a good correlation between serum PSA 
concentrations and clinical stage in patients with prostate cancer. For example, one 
large study, which examined 703 men undergoing radical prostatectomy for prostate 
cancer, reported that 75% of patients whose semm PSA concentration were less than 
4ng/ml, 53% of patients with PSA concentrations between 4 and 1 Ong/ml, 26% of
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patients with PSA concentrations between 20 and 30ng/ml and only 8% of patients 
with serum PSA concentrations between 30 and 40ng/ml had organ confined disease 
(Partin et al, 1993). Furthermore, the authors reported that the incidence of capsular 
penetration, seminal vesicle involvement and lymph node métastasés rose as PSA 
concentrations increased (Figure 1.6).
PSA and stage (Data from Partin et al 1993)
0)I
80
70
60
50
40
30
20
10
0
0-4 4-10 10-20 20-30 30-40
Organ confined 
' Nodal disease
PSA ng/ml
Figure 1.6 The relationship between PSA and extent of disease
Similarly, Gleave and co-workers reported that no patients with PSA concentrations 
below 1 Ong/ml had evidence of bone métastasés on bone scan, whereas 5% of patients 
with PSA concentrations between 10 and 20 ng/ml, 8% of patients with PSA 
concentrations between 20 and 50ng/ml and 40% of patients with serum PSA 
concentrations above 50ng/ml had evidence of bone métastasés (Gleave et al, 1996) 
(see Figure 1.7 on next page).
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Biopsy characteristics and staging
The vast majority of patients who are diagnosed with prostate cancer will have their 
diagnosis confirmed by biopsy. These tissue samples provide valuable information 
about the tumour, which may be used to help predict stage.
Gleason score.
Partin and co-workers (1993) examined 703 men undergoing radical prostatectomy 
for clinically localised prostate cancer. They reported that preoperative Gleasons 
scoring of biopsy material correlated strongly with final pathological stage in patients 
with low or high-grade disease. However, the majority of prostate cancer patients 
were reported to have intermediate grade tumours (Gleasons scores between 5 and 
seven). For example, o f the 64 patients with low grade tumours (Gleasons score 2-4), 
49 had organ confined disease, 12 had extra capsular extension, 2 had seminal vesicle 
involvement and one had lymph node métastasés. In contrast, o f the 38 patients with
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high-grade disease (Gleasons score 8-10), only 5 had organ-confined disease, 9 had 
extracapsular extension, 8 had seminal vesicle involvement and 16 had nodal disease 
(Figure 1.8).
High and low grade tumour characteristics (Data from Partin *K
1993)
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Figure 1.8 The relationship between tumour grade and stage 
Tumour volume
It has long been recognised that low volume prostate cancers are far less likely to 
extend beyond the prostate capsule than high volume tumours (Voges et al, 1992). At 
present, imaging studies allow the clinician to accurately measure the total volume of 
the prostate gland, but not the tumour volume itself. As a result, some authors have 
advocated using the number or proportion of tumour positive core biopsy specimens 
as a surrogate indicator of tumour volume. For example, Ackerman and co-workers 
(1993) examined candidates for radical prostatectomy. They found that only 12% of  
patients with a single positive core biopsy had positive margins following surgery, 
compared with 50% of patients who had between 2 and 6 positive core biopsies.
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Combining clinical predictors of stage.
There are a number of clinical indicators, which can be used to predict stage. 
However, all o f these parameters have limitations when used in isolation. Several 
authors have attempted to combine some of these factors to improve their predictive 
value. For example, Partin and co-workers (1993; 1997) showed that the combination 
of clinical stage, preoperative PSA concentrations and Gleason scores improved the 
ability to predict pathological stage. They also constmcted probability plots and 
nomogi'ams to assist the preoperative prediction of the final pathological stage for 
patients with clinically localised prostate cancer.
Clearly this infonnation is important to enable clinicians and patients to make 
more informed decisions about potential therapeutic options and to better understand 
the likely outcome of treatment.
1.9 Management of prostate cancer.
1.9.1 The management of localised disease.
The optimal management o f prostate cancer is detennined primarily by tumour stage 
and grade, age, general health and individual patient preference. The main strategies 
for managing localised prostate cancer include watchful waiting, external beam 
radiotherapy, brachytherapy and radical prostatectomy. However, there is ongoing 
debate amongst surgeons and oncologists about the relative merits of surgery and 
radiotherapy. The increasing numbers of localised prostate cancers, which are being 
detected by PSA testing, fuels this debate.
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Watchful waiting
The watchful waiting approach to the treatment of localised prostate cancer is based 
on the knowledge that a large proportion of patients with prostate cancer will not die 
from the disease. Furthermore, aggiessive treatment, such as radiotherapy or surgery, 
is often associated with considerable morbidity. Watchful waiting allows clinicians to 
monitor a patient’s progi ess and inteiwene if the patient develops symptoms or 
evidence of disease progression.
Much of the information about the expectant management of prostate cancer 
comes from studies carried out in Sweden. For example, Johansson (1994) evaluated 
suiwival in more than 220 Swedish men with early stage prostate cancer. He reported 
that only 10% of the patients, managed conservatively, died of their cancer over a ten- 
year period. In contrast, Aus (1994) suggested that prostate cancer was a far more 
aggressive disease and that there was considerable morbidity and mortality associated 
with expectant management, hi his study, almost two thirds of patients treated 
conservatively eventually died from their cancer.
The apparent differences between these studies probably reflect in part the 
tumour and patient characteristics of the two cohorts and the length of follow-up. It is 
therefore of interest that Zietman and colleagues (2001) recently reported that over 
half of men initially managed conseiwatively were commenced on active treatment 
within five years. Therapy was most commonly initiated following small but 
inevitable rises in circulating PSA concentrations. This observation reflects the 
unease that many patients and clinicians have in monitoring disease progress whilst 
withholding potentially curative treatment.
Overall, tumour grade appears to be the most important detemiinant of 
survival in patients with clinically localised prostate cancer treated conservatively.
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For example, Denis (2000) compared sui'vival in cohorts of patients with localised 
prostate cancer treated either conservatively, or with surgery or radiotherapy and 
found that grade was a strong predictor of 10 year survival. Furthermore, in patients 
with low-grade tumours (Gleasons score 2-4), ten-year cancer specific suiwival was 
comparable in all three patient gi'oups. In contrast, patients with high-grade tumours 
(Gleasons score 8-10) treated conservatively had a poorer ten-year survival than those 
treated with either surgery or radiotherapy.
In conclusion, watchful waiting is probably an appropriate treatment option 
for some patients with low volume, low grade localised prostate cancers in whom life- 
expectancy does not exceed 10 years.
External beam radiotherapy
Radiotherapy is a potentially curative treatment in patients with localised prostate 
cancer. It is Imown that both increasing T-stage and a high gleason score 
compromises the chance o f achieving cure with radiotherapy (Bagshaw et al, 1988; 
Roach et al, 1999). However, circulating PSA concentration at diagnosis is perhaps 
the most significant predictor of clinical outcome in patients being treated with 
radiotherapy. For example, Lee and colleagues (1995) reported that 86% of patients 
with pre-treatment PSA concentrations less than 15ng/ml had no evidence of 
biochemical relapse at 3 years, compared to only 38% of patients with PSA 
concentrations greater than 15ng/ml.
These studies suggest that the ideal candidate for radiotherapy would have an 
early stage, low-gi*ade tumour and a pre-treatment PSA concentration less than 
15ng/ml. Radiotherapy is therefore often the preferred treatment option in elderly 
patients or patients with significant co-morbidity which might make them unsuitable 
for radical surgery.
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Radiotherapy is, however, not without risks and side effects. Shipley and 
colleagues (1994) reported a 0.2% mortality rate associated with treatment, a 0.9% 
incontinence rate and a potency rate of 33-60% following radiotherapy. Radiotherapy 
can also induce inflammatory changes in the rectum and bladder leading to proctitis, 
cystitis and urethral stricture formation.
Prostate specific antigen is used to assess the response to radiotherapy in 
patients with prostate cancer. For example, it has been reported that if  a PSA nadir of 
<0.5ng/mL was achieved, the biochemical relapse rate, defined as tliree successive 
PSA rises after reaching a nadir, was <10%. In contrast, patients who failed to reach 
this nadir value had a biochemical relapse rate of around 54% (Zietman et al, 1996).
To date there have not been any randomised controlled trials comparing the 
results of external-beam radiotherapy and radical prostatectomy. Historically, 
comparisons between these treatment options have often reported results which favour 
surgery. However, patients undergoing surgery are more likely to undergo lymph- 
node dissection than those undergoing radiotherapy and are therefore more likely to 
be staged conectly. Since lymph-node métastasés are unlikely to be detected in 
patients undergoing radiotherapy, there is an intrinsic suivival bias in favour of 
surgery. In many recent studies, where staging is thought to be more accurate, similar 
results are reported for surgery and radiotherapy. For example, Kupelian et al (2002) 
reported that the eight-year biochemical relapse free survival rates for surgery and 
radiotherapy were 72% and 70% respectively.
Brachytherapy
Brachytherapy is an alternative method of delivering high radiation doses directly to 
the prostate whilst minimising exposure to the surrounding non-target tissues. 
Brachytherapy for the treatment of prostate cancer was popularised by Whitmore and
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colleagues (1972). However, despite initial reports of encouraging local control and 
smvival, there were a high proportion of late local failures. Interest was regenerated 
in the teclinique when Holm and colleagues (1983) described the use of transrectal 
ultrasound (TRUS) to guide the implantation of brachytherapy seeds. With a half-life 
of around 60 days and low-energy photon emissions, Iodine’ is the most commonly 
used implant in brachytherapy (Plowman, 2001).
Ragde and co-workers (1997) reported that for patients with low-gi'ade 
localised disease the results of brachytherapy were comparable to those of radical 
prostatectomy. The ability to target dose delivery represents the gi'eatest strength of 
brachytherapy, but is also its potential weakness, since any disease that extends 
beyond the range of the implant will not receive effective irradiation.
The American Brachytherapy Society recently published guidelines for the use 
of brachytherapy (Nag et al, 1999). They concluded that patients with Tl-T2a 
disease, a Gleason score of 2-6 and a pre-treatment PSA concentration of less than 
1 Ong/ml are good candidates for brachytherapy monotherapy. However, patients with 
T2b/c disease, a Gleason score of greater than 6 or a pre-treatment PSA concentration 
greater than 20ng/ml, are better treated with a combined treatment regime.
Radical prostatectomy.
Radical prostate surgery offers the advantage of a single potentially curative 
inteivention in patients with localised prostate cancer. The first radical prostatectomy 
was performed by Hugh Hampton Young in 1904. The procedure involved the 
surgical removal of the prostate gland and seminal vesicles followed by the formation 
of an anastomosis between the bladder neck and the uretln al stump. However, prior 
to the late 1970's the surgical anatomy o f the prostate was poorly understood. 
Complications including haemorrhage, stricture foimation, incontinence and
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impotence were therefore common and this deterred many urologists from offering 
surgery as treatment.
More recently, a series of advances in our understanding of the relevant 
anatomy has reduced complication rates and most urologists now regard radical 
prostatectomy as the “gold standard” in the treatment of early stage disease. As a 
result, in the US, the proportion of newly diagnosed prostate cancer patients treated 
with surgery doubled between 1989 and 1991 (Lu-yao et al, 1993).
Nevertheless, complications associated with radical prostatectomy remain.
One study, which evaluated 10,604 patients who underwent radical prostate surgery 
between 1991 and 1994, reported a post-operative mortality rate of 1% and a 
complication rate of 25% (Lu-yao et al, 1999).
Incontinence and erectile dysfunction are the two major long-term 
complications of radical prostatectomy. Many patients report some degree of urinary 
incontinence in the initial postoperative period. However, Walsh and colleagues 
recently reported that urinary continence gradually improves over the first 12 months 
and that at one year 93% of patients were dry (Walsh et al, 2000).
Impotence rates following surgery vary widely depending on the patient’s age, 
the experience of the surgeon and whether a neive sparing prostatectomy has been 
performed (Pirtsklialaishvili et al, 2001). For example, Stanford and colleagues 
(2000) recently reported that almost 60% of patients undergoing radical prostatectomy 
were impotent at 18 months. Recently, however, the use of sildenafil citrate (Viagra) 
has been shown to be effective in treating erectile dysfunction in a large proportion of 
patients undergoing neive-sparing surgery (Zippe et al, 1998).
There are many studies examining the outcome of patients following radical 
prostatectomy. For example, Lu-Yao and Yao (1997) reported that the 10-year.
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disease specific suivival rate following surgery was 94%, 87% and 67% for well, 
moderately and poorly differentiated tumours. The corresponding results for patients 
treated conservatively or with radiotherapy were 93%, 77%, 45% and 90%, 76% and 
53% respectively.
Patients who are considered good candidates for radical prostatectomy are 
likely to be men who have localised but clinically significant disease in whom life 
expectancy is estimated to be at least 10 years. In such patients the expected benefits 
of surgery out-weigh the risk of morbidity. In summary, radical prostatectomy is still 
considered the “gold standard” treatment for clinically localised disease in patients 
who are younger than 70 years, are fit for surgery and have reasonable life 
expectancy.
Neoadjuvant hormone therapy.
Treatment with neoadjuvant hormone therapy is known to result in shi'inkage of the 
prostate gland and a rapid reduction in the concentration of circulating PSA. When 
used prior to prostatectomy, neo adjuvant hormone therapy reduces the incidence of 
positive surgical margins, but has not been shown to improve survival or delay 
disease progi'ession.
In contrast, there are a number of studies, which suggest that the use of 
neoadjuvant therapy prior to radiotherapy improves clinical outcome. For example, 
Zietman and colleagues (1997a) compared men treated with radiotherapy or with a 
combination of radiotherapy and neoadjuvant homione therapy. They reported that at 
five years the local control and disease-free rates for the radiotherapy and the 
combination group were 54% vs. 29% and 36% vs. 15% respectively. The optimal 
sequence and length of treatment with neoadjuvant hormone therapy however has not 
been established.
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1.9.2 Treatment of locally advanced prostate cancer
The optimal management of locally advanced prostate cancer also remains 
controversial. In general, patients described as having locally advanced disease have 
T3 or T4 disease with no evidence of lymph node or distant métastasés. At this stage, 
the tumour extends through the prostatic capsule and may involve surrounding 
structures. A definitive treatment approach for patients with locally advanced disease 
remains unclear for several reasons. Firstly, the natural history of such cancer is not 
well understood. The longest study of untreated locally advanced prostate cancers 
was recently reported by Johansson and colleagues (1997). This study included 183 
patients with T3 or T4 disease who were treated initially with obseivation. At 15 
years, progression-free survival and disease-specific survival were reported as being 
46% and 56%, respectively. Secondly, no randomised clinical trials have compared 
equivalent patients treated with different therapeutic modalities.
Single modality therapy for locally advanced disease
Radiotherapy.
External beam radiotherapy has traditionally been considered the treatment of choice 
in patients with locally advanced prostate cancer. Sclmiidt and co-workers (1986) 
reported a marked increase in the use of radiotherapy for the treatment of locally 
advanced disease from 9.1% in 1974, to 33.6% of patients in 1984. In general, good 
local control, low morbidity and overall suivival comparable to other treatment 
modalities have been reported. For example, in one study, which evaluated 216 
patients with locally advanced disease treated with radiotherapy, it was reported that 
70% of patients remained free of local recurrence at 5 years, 65% at 10 years and 69%
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at 15 years (Hanks et al, 1994). Overall survival rates were 56%, 32% and 23% at 5, 
10 and 15 years respectively.
However, more recent studies earned out in the PSA era suggest higher levels of 
persistent disease. One study using circulating PSA concentrations >1 ng/ml as 
evidence of treatment failure reported that of 589 patients treated with radiotherapy, 
only 21% were biochemically free of disease at 10 years (Zietman and Shipley, 1997). 
Furthermore, post-irradiation prostatic biopsies have been shown to contain residual 
tumour in up to half of patients (Oh and Kantoff, 1999). These findings probably 
represent the inability of external beam radiotherapy to eradicate most locally 
advanced cancers.
Radical prostatectomy
The use of radical surgery to treat locally advanced prostate cancer is controversial 
since the likelihood of achieving cure is low. Indeed, up to half of patients with T3 
disease undergoing staging lymphadenectomy prior to surgery have evidence of 
lymph node métastasés (Oh and Kantoff, 1999). Furthermore, Bosch and colleagues 
estimated that less than 30% of patients undergoing radical surgery for T3 disease had 
both clear resection margins and no evidence of lymph node métastasés (Bosch et al, 
1987). These reports suggest that radical prostatectomy is not an effective treatment 
in around 70% of patients with T3 disease.
Androgen deprivation therapy.
Androgens are known to stimulate growth in both nonnal and malignant prostate 
tissue. When androgens are withdrawn, cellular proliferation is inhibited and 
apoptosis may be promoted.
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Neoadjuvant honnone therapy is given prior to definitive local treatment. GnRH 
receptor agonists, such as goserelin, have been used in the treatment o f prostate 
cancer. These drugs mimic GnRH, a honnone produced by the hypothalamus. This 
hoimone stimulates the release of FSH and LH from the anterior pituitary gland. LH 
in turn stimulates the production of androgens in the testes. Administration of these 
GnRH agonists initially causes a surge in circulating concentrations of testosterone 
and dihydrotestosterone which can lead to tumour flare. Eventually, however these 
agonists dowm*egulate the hypothalamic-pituitary axis and consequently inhibit the 
production of LH and therefore androgen production. Anti-androgens are often given 
during the initial treatment period to limit the clinical sequelae related to tumour flare.
Combined treatment regimes for the treatment of locally advanced prostate cancer.
Androgen deprivation therapy and radiotherapy
There are a number of theoretical advantages in combining external-beam 
radiotherapy and androgen deprivation therapy. Elimination of androgen dependent 
prostate cancer cells increases the likelihood that a given dose of radiation will 
successfully treat the entire local tumour burden. Indeed, it is thought that androgen 
deprivation therapy and radiotherapy may have a synergistic effect in promoting 
cancer cell apoptosis. Furthermore, hormone therapy would potentially treat any 
undetected micrometastatic disease.
Several interesting studies have evaluated the combined use of radiotherapy 
and hormone treatment in the adjuvant and neoadjuvant setting. For example, 
Pilepich and co-workers (1997) randomised patients with T3 and N1 disease to 
receive adjuvant post-irradiation goserelin. Disease-fi*ee survival was significantly 
higher in those patients receiving goserelin. There was no difference in overall
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survival between the two patient cohorts. However, when a sub group of patients 
with high grade tumours were examined survival was gi'eater in the patients receiving 
hormone therapy. Bolla and co-workers (1997) conducted a randomised trial 
comparing radiotherapy alone with radiotherapy plus goserelin for tliree years. Five 
year survival was significantly higher in those patients receiving combined treatment.
Androgen deprivation therapy and radical prostatectomy.
One of the main problems associated with the use of radical surgery in the treatment 
of prostate cancer is the prevalence of non-organ confined disease. Several studies 
have now reported that the use of neo-adjuvant hormone therapy prior to radical 
prostatectomy significantly reduces the incidence of positive surgical resection 
margins and prostatic volume. Unfortunately, none of these studies has shown any 
improvement in survival, seminal vesicle or lymph node involvement or biochemical 
disease free survival (Chodak et al, 2002). Furthermore, despite reducing prostatic 
volume, neo-adjuvant hormone therapy has not been shown to improve the ease of 
surgery (Soloway et al, 1995).
F9B The management of metastatic prostate cancer
Adenocarcinoma of the prostate gland most frequently metastasises to the well 
vascularised areas o f the axial skeleton such as the spine, pelvis, ribs, skull and the 
proximal ends of the long bones. Bone métastasés may cause intermittent or constant 
bone pain, bone mannw failure, hypercalcaemia, pathological fi'actures or spinal cord 
compression. Symptoms associated with these features of advanced disease can lead 
to a considerable reduction in the quality of life of affected patients.
Androgen deprivation therapy
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There is now extensive evidence to support the obseiwation first reported by Huggins 
and Hodges (1941) that androgen ablation is an effective palliative treatment in men 
with symptomatic metastatic prostate cancer. The clinical benefits of hormonal 
manipulation include a reduction in bone pain, an improvement in obstmctive urinary 
symptoms, a reduction in prostatic bleeding, and a decrease in circulating PSA 
concentrations. As a result, hoimone treatment is the mainstay of treatment in men 
with metastatic disease. However, the effects of androgen ablation on patients with 
prostate cancer are temporary. Such patients ultimately become umesponsive to 
androgen ablation and are then classified as having hormone-refractory disease. The 
median time hnm commencing hormonal therapy to developing hormone refractory 
disease is around 18 months. The median survival of patients with hoimone 
refractory disease is only one year (Fournier, 1996).
Androgen deprivation therapy itself can be responsible for significant side- 
effects including loss of libido and potency, hot flushes, anaemia, alopecia, fatigue 
and psychological illness. Furthermore, Daniell (1997) recently reported that men 
treated with long teim hormone therapy had reduced mineral bone density compared 
to age-matched controls, hideed such patients were said to be at higher risk of 
developing osteoperotie fractures than pathological fractures resulting from metastatic 
bone disease. As a result of these factors, there is ongoing debate about the impact of 
hormone treatment on survival and the optimal timing for initiation of androgen 
deprivation therapy.
An important study earned out by the Medical Research Council (1997) aimed 
to answer some of these questions. The effect of immediate or delayed hormone 
therapy was evaluated in 261 men with asymptomatic métastasés, 503 men with 
locally advanced disease and 174 men whose metastatic disease status was unlmown.
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Although the study initially reported improved survival among the cohort of patients 
receiving early hormone therapy, compared to those patients in whom treatment was 
deferred, this suiwival advantage was lost with additional follow-up. There was 
however, a statistically significant reduction in complications such as pathological 
fractures, spinal cord compression and ureteric obstruction in patients receiving early 
hoimone treatment.
Chemotherapy in patients with hormone refractory prostate cancer 
Traditionally hoimone-reffactory prostate cancer was thought to be a chemotherapy- 
resistant disease. However, recently chemotherapy has been shown to provide 
effective palliation of symptoms in some patients with hormone refractory disease.
Mitoxantrone is an amino anthiacenedione and was originally used in the 
treatment of myelogenous leukaemias. Tamiock and co-workers (1996) randomised 
patients with hoimone refractory prostate cancer to receive either prednisone alone or 
prednisone in combination with mitoxantrone. They reported a statistically 
significant improvement in the palliation of symptoms, including bone pain, in those 
patients receiving combined steroid and mitoxantrone therapy. The length of 
effective palliation was also reported to be longer in the patients receiving 
combination therapy. Mitoxantrone combined with prednisone is therefore a 
therapeutic option in selected patients with symptoms related to hoimone-refractory 
prostate cancer.
Taxanes have been shown to induce cell death in prostate cancer cell lines. 
This observation has generated interest in the use of taxane based chemotherapy 
regimes in vivo. For example Beer and colleagues (2001) sought to investigate the 
activity and toxicity of weekly docetaxel in patients with hormone independent 
prostate cancer and bone pain. They reported that approximately 50% of patients
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receiving treatment experienced a reduction in bone pain. In a similar proportion of 
patients there was a >50% reduction in circulating PSA concentrations following 
treatment. The authors concluded that docetaxel was well tolerated in patients with 
honnone refractory disease and had significant therapeutic activity as measured by 
pain relief, reduction in PSA and reduction in measurable disease.
Bisphosphonates.
Bisphosphonates bind to hydroxyapatite crystals in bone and resist bone resorbtion. 
There is evidence to suggest that bone reabsorbtion may be necessary to allow the 
foundation of bone métastasés in patients with prostate cancer. Treatment with 
bisphosphonates has been shown to be associated with a reduction in the number and 
activity of osteoclasts, probably thi'ough a direct effect on osteoclast activity as well 
as indirect effects on osteoblasts and macrophages. The net effect of bisphosphonate 
treatment is therefore a reduction in excessive bone turn-over and preservation of 
bone structure and mineralization.
Bisphosphonates have been shown to have a number of potential roles in 
patients with prostate cancer. Some studies have suggested that the use of 
bisphosphonates can inhibit the demineralisation of bone which is often associated 
with androgen deprivation therapy (Smith, 2003). Fmlhennore, in advanced disease, 
bisphosphonate treatment has been shown to be effective in controlling 
hypercalcaemia and bone pain associated with the presence of bone métastasés (Saad 
et al, 2002). There is also some experimental evidence to suggest that 
bisphosphonates may directly inliibit tumour activity and delay the time to the first 
skeletal event (Goodin et al, 2002).
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Radiotherapy
Radiotherapy can provide effective palliation for pain related to bone métastasés. 
There are two main radiotherapy modalities which are of use in the treatment of 
metastatic prostate cancer. These include external beam radiotherapy and 
radionucleotide therapy.
External beam radiotherapy has long been known to have a favourable effect 
on pain caused by bone métastasés. Local field radiation may be given as a single 
fraction of 8Gy, as five fractions of 4Gy or as ten fractions 3 Gy. The palliative effect 
begins within a few days and lasts around 4 months. However reports suggest that 
only approximately 25% of patients experience a complete cessation of pain (Di 
Lorenzo et al, 2003). Furthermore, in patients who develop spinal cord compression 
as a result o f bone métastasés, urgent external beam radiotherapy may be used to 
prevent permanent neurological injury.
Radionucleotide therapy is of use in patients with multiple painful bone 
métastasés. It involves the intravenous administration of a bone seeking radioactive 
pharmaceutical. These compounds, such as Strontium 89, are then taken up by areas 
of bone undergoing rapid turnover, such as skeletal métastasés. Such treatment 
therefore delivers targeted radiation directly to bone métastasés.
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2.0 The inflammatory response to cancer
2.0.1 The cell-mediated response
Host immune cells are able to eliminate foreign cells and altered self-cells by 
mounting a cell-mediated response which results in lysis of the target cells. There are 
two main mechanisms by which the host immune cells are able to initiate cell death. 
Firstly, cell destruction can be mediated by cytotoxic T-lymphocytes (CTL's) in 
response to a specific antigenic stimulus. Secondly, a non-specific cytotoxic response 
can be generated by cells such as natural killer cells (NK) and macrophages. Both 
these types of immune response are mounted in response to the presence o f cancer 
cells and virus-infected cells.
This cell-mediated response is largely carried out by thymus-derived (T)- 
lymphocytes. In the circulation T-lymphocytes constitute 60-70% of peripheral 
lymphocytes. T-lymphocytes are also found in the paracoitical areas of lymph-nodes 
and peri-arteriolar sheaths of the spleen. Each T-lymphocyte is genetically 
programmed to recognise a specific cell-bound antigen by means of an antigen- 
specific T-cell receptor. What distinguishes the T-cell receptor from membrane- 
bound antigen on B-lymphocytes is that it recognises antigen only when the antigen is 
associated with a self molecule encoded by genes within the major histocompatibility 
complex (MHC). Whereas the B-cell is capable of binding soluble antigen, the T-cell 
system is restricted to binding antigen on self-cells. This antigen may be displayed on 
the surface of antigen presenting cells or on vims-infected cells, cancer cells or grafts.
T-cell receptors are non-covalently linked to a cluster of five polypeptide 
chains, lefened to as the CD3 molecular complex. The CD3 proteins are non-variable
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and do not bind antigen but are involved in T-lymphocyte signalling after antigen 
binding.
hr addition to CD3 proteins, T-lymphocytes express a variety of other 
antigens, including CD4, CDS and many so-called accessory molecules, such as the 
CD2, CD28 and CD40 ligand. O f these CD4 and CDS are particularly important. 
These antigens are expressed by two mutually exclusive T-lymphocyte subsets. 
Lymphocytes expressing the CD4 antigen account for approximately 60% of CD3+ 
T-lymphocytes. The majority of the remaining CD3+ lymphocytes express the CDS 
antigen.
During the antigen presentation process, CD4 antigen molecules bind to 
portions of class II major histocompatibility complexes which are expressed on 
antigen presenting cells including macrophages, dendritic cells and B-lymphocytes.
In comparison, CD8 molecules bind to portions of the class I MHC. Class I MHC 
molecules are found on the majority of nucleated cells. For this reason CD4+ helper 
cells can recognise antigen only if associated with a class II MHC, whereas CD8+ 
lymphocytes can only recognise cell-bound antigens associated with class I MHC 
antigens.
CytotoxicT-Lymphocyte-mediated immunity
Activation of cytotoxic T-lymphocytes generates a population of cells with the ability 
to produce target-cell lysis. Most cytotoxic T-lymphocytes express the CDS antigen 
complex and are therefore class I MHC restricted. As the vast majority o f nucleated 
cells express the class I MHC, these lymphocytes have the potential to recognise and 
eliminate abnormal cells from most body tissues.
Non-activated cytotoxic T-lymphocytes are incapable of killing target cells 
and are therefore referred to as cytotoxic T-lymphocytes precursors to denote their
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functionally immature state. Only after a cytotoxic T-lymphocyte has been 
immunologically activated will it develop the cell lytic capability of a mature cell.
Activation of a cytotoxic T-lymphocyte precursors requires two signals. The 
first signal occurs when the T-cell receptor and the CDS antigen on the immature 
lymphocytes interact with an antigenic peptide on the class I MHC of a target cell. A 
second signal is provided by the release of cytokines from activated CD4+ T-helper 
cells. The most important of these cytokines appears to be interleukin-2 (IL-2) 
although others such as interleukin-6 and interleukin-4 may also have a role. 
Activation of IL-2 receptors on the precursor cell membranes stimulates proliferation 
and differentiation to produce mature cytotoxic T-lymphocytes. Precursor cells which 
have not encountered an antigenic stimulus do not express IL-2 receptors and 
therefore cytotoxic T-lymphocyte precursors require antigenic priming before they 
can respond to the IL-2 signal. This safe-guard ensures that only precursor cells 
responding to a specific antigenic stimulus are activated and undergo clonal 
expansion. Following antigenic stimulation cytotoxic T-lymphocytes are dependent 
on IL-2 to induce proliferation. Circulating IL-2 concentrations fall in response to 
antigen clearance and this triggers apoptosis of the antigen-specific cytotoxic T- 
lymphocytes clones. This mechanism ensures that the immune response is terminated 
promptly, following elimination of the biological stimulus, and this in turn limits the 
likelihood of collateral damage to healthy tissue and cells.
The destruction of a target-cell by activated cytotoxic T-lymphocytes requires 
a carefully orchesti'ated sequence of events culminating in target-cell lysis. The main 
phases of this sequence include conjugate formation, membrane attack, cytotoxic T- 
lymphocytes dissociation and target-cell destruction. When a cytotoxic T-lymphocyte 
comes into contact with an appropriate target cell the cells interact to fonn a
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conjugate. The integrin receptors LFA-1 on the surface of the cytotoxic T- 
lymphocytes bind to the intercellular cell-adhesion molecules (ICAMs) on the target­
cell membrane. Antigen activation of a cytotoxic T-lymphocytes by the target cell 
transfonns LFA-1 from a low avidity state to a high avidity state resulting in cytotoxic 
T-lymphocyte-target cell binding. This mechanism ensures that cytotoxic T- 
lymphocytes bind only to cells which provide an appropriate antigenic stimulus. LFA- 
1 remains in a high avidity state for around five-10 minutes before reverting back to 
its original low-avidity state. This reduction in LFA-1 avidity is thought to promote 
cytotoxic T-lymphocyte-target-cell dissociation
Following cell binding, vesicles containing perforin are released into the 
junctional space between the two cells. As the perforin molecules make contact with 
the target-cell membrane they polymerise to fomi pores within the cell membrane. 
These pores are thought to facilitate the entry of further lytic substances which 
destroy the target cell. Cell death occurs approximately 15minutes to three hours after 
cellular dissociation.
Activation of CD4+ T-helper cells
Both the cell-mediated and humoral immune responses are dependent on activation of 
T-helper cells. This process starts when antigen receptors on the T-helper cells come 
into contact with antigenic peptide in combination with a MHC II complex. These 
complexes occur on the surfaces of antigen presenting cells such as macrophages, B- 
lymphocytes and dendritic cells. Such cells internalise antigen by phagocytosis or 
endocytosis before re-expressing part of that antigen on the cell surface in conjunction 
with a MHC II complex. The T-helper cell is then able to recognise the antigen 
associated with the MHC on the surface of the antigen-presenting cell. This 
recognition generates a signal which results in the production of interleukin-2 which
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in turn results in clonal expansion of the T-helper cell population and activation of 
cytotoxic T-cells.
Natural killer cell-mediated cytotoxicity
Natural killer (NK) cells comprise approximately 5-10% of the circulating 
lymphocyte population. These cells have been implicated in anti-viral immunity and 
are involved in the host defence against tumour cells. The origin of NK cells is not 
clear as they express some membrane markers of T-lymphocytes and also some 
membrane markers of monocytes and gi anulocytes. NK cells appear to kill tumour 
cells and virus-infected cells by a process similar to CTL mediated lysis. After a NK 
cell adheres to the target cell, release of perforin-containing gi'anules occurs. This 
release of perforin causes target cell membrane damage which in turn triggers target 
cell death.
Since NK cells do not express antigen specific receptors, a mechanism exists 
to prevent them from attacking normal cells. It is known that tumour and virus- 
infected cells generally express lower levels of class 1 MHC molecules than normal. 
It has been suggested that NK cells may have membrane receptors for class 1 MHC 
molecules, and that activation of these receptors inhibits target cell destruction. This 
mechanism means that when NK cells encounter normal cells, cell lysis is inhibited 
by activation of the class 1 MHC receptors. In contrast when a tumour cell or virus 
infected cell with reduced class 1 MHC expression is encountered cell lysis is 
initiated leading to the death of the target cell.
The cell-mediated immune response in cancer.
The immune system is a complex defence system which has evolved primarily to 
protect the body against infection by micro-organisms and not necessarily against
57
malignancy. Despite this, the immune system is thought to provide protection against 
many cancer types. The immune sui*veillance hypothesis proposes that the immune 
system continually sm*yeys the body for malignancy, eliminating many or most 
tumours, and possibly slowing the growth of others (Burnet, 1967). Indeed as early as 
1909, Paul Eludich had proposed the concept of cellular immunity directed against 
tumours cells (Eludich, 1909). The tumour suiweillance hypothesis fell into disrepute 
after reports that non-virus related cancers were not increased in immunodeficient 
animals and humans. Furthennore, some studies reported that the incidence of cancer 
was not increased in (nu/nu) mutant mice which lack a thymus gland and are 
consequently deficient in most T-lymphocytes (Stutman, 1974). In retrospect, 
however, the conclusions of these studies are flawed as the animals studied did not 
completely lack T-lymphocytes.
It is now generally believed that the cell-mediated immune response does have 
an important role to play in anti-tumoral immunity and there is increasing evidence to 
support this theory. For example, it has been shown that patients suffering from some 
types of cancer produce T-cell lymphocyte clones specific for tumour antigens (Boon 
et al, 1994). Moreover, some authors report tumour regression in patients from whom 
tumour infiltrating lymphocytes are haiwested, expanded in vitro and then re-infused. 
Furthermore, a substantially increased spontaneous tumour rate has been reported in 
aged mutant mice specifically lacking T and B-lymphocytes, as a result o f a targeted 
mutation on the Rag-2 gene (Shankaaran et al, 2001). Other studies have 
demonstrated an increased incidence of certain tumour types in mice lacking perforin, 
the pore forming protein which is an essential component of the cytotoxic T- 
lymphocyte and natural killer cell-mediated response (Van der Broek et al, 1996).
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It is also reported that, in many human cancers the degree to which the tumour 
is infiltrated with inflammatory cells predicts recurrence-free and cancer-specific 
sui'vival. For example, the presence o f macrophages around lung and gastric cancers 
is associated with reduced tumour progression (Ropponen et al, 1997). In many other 
solid tumours including colorectal (Ropponen et al, 1997), breast (Aaltomaa et al, 
1992) and melanoma (Clark et al, 1989), tumour lymphocyte infiltration has been 
shown to have prognostic implications. Much of the research investigating the 
prognostic importance of tumour infiltrating lymphocytes (TILs) in predicting 
sui*vival has been undertaken in patients with colorectal cancers.
The colorectal model
The survival advantage conferred by a pronounced tumour lymphocytic infiltration in 
large bowel cancer has been known for many years, hideed, MacCarty described this 
relationship as early as 1931. Similar observations have been made in many 
subsequent studies. For example, in 1987, Jass and colleagues devised a prognostic 
scoring system which identified four independent pathological variables including 
lymphocytic infiltration which predicted outcome. It was suggested that this new 
system was superior to the well established Dukes classification because it placed 
twice as many patients into groups which provided a confident prediction of clinical 
outcome. In addition to providing useful prognostic information the Jass classification 
allowed clinicians to identify groups of patients who might receive the most benefit 
fi'om adjuvant chemotherapy.
For such a system to be clinically useful it must be possible to reliably 
reproduce the results. Jass and co-workers reported interobserver agreement to be fair 
to excellent. However these assessments were made by comparing specialist
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colorectal pathologists. When the system was re-assessed using general pathologists, 
the intra-observer and inter-observer agreement was reported as being little better than 
chance (Dundas et al, 1988). The technical difficulties in using the Jass classification 
system and problems with its reproducibility have meant that it has not become 
widely established in hospital laboratories. It is of interest, however, that the Jass 
classification is the only pathological system which makes an assessment of the host 
response to the presence of the tumour. Similar findings were subsequently reported 
by Nielsen and co-workers who demonstrated that poor inflammatory tumour 
infiltrate was associated with poor outcome in patients undergoing surgery for 
primary operable colorectal cancer (Neilsen et al 1999).
More recently, the ability to identify lymphocyte subsets, by the use of 
specific immunohistochemical staining, has led to renewed interest in this area. For 
example, Naito and his colleagues (1998) reported that, in a cohort of 131 patients 
with colorectal cancer, the pattern of lymphocytic infiltration o f the tumour had 
important prognostic implications. More specifically they reported that the degree to 
which CD8+ lymphocytes invaded the tumour, predicted suiwival. Patients in whom 
the CD8+ lymphocytes infiltrated the cancer cell nests did better than those patients in 
whom the lymphocytes only invaded the stroma or appeared at the tumour margin. In 
contrast, other studies have suggested that CD4+ lymphocytes are more important 
than CD8+ cells in deteimining outcome in patients with colorectal cancer. For 
example, Ali and co-workers (2004) reported that, in patients with colorectal cancer, a 
marked CD4+ lymphocyte infiltration of the tumour was associated with good 
prognosis.
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The cell mediated response in renal carcinoma.
Renal cell carcinoma is one of the few cancer types in which immunotherapy is 
routinely used in patients with disseminated disease. As a result, the role of the cell- 
mediated response in patients with renal carcinoma is an area of great interest. 
However, the two main studies which have investigated the role of tumour infiltrating 
lymphocytes in renal carcinoma have reported that a marked T-cell response was 
associated with poor sui-vival (Nakano et al, 2001; Bromwich et al, 2003). It was 
suggested that in renal cell carcinoma at least, tumour-lymphocyte infiltration may be 
determined by tumour grade or by tumour cytokine production rather than a reflection 
of anti-tumoral immunity.
The cell mediated response in prostate cancer
The relationship between the presence of an inflammatory cell infiltrate and prognosis 
has only recently been investigated in patients with prostate cancer. To date, few 
studies have addressed this area of research, and their results are somewhat 
contradictory.
The largest study, undertaken by Vesalainen and colleagues (1994), examined 
325 patients with prostate cancer; of the patients studied, 101 were found to have 
metastatic disease at the time of diagnosis. Histological specimens were assessed and 
divided into tliree groups according to the magnitude of the lymphocytic infiltrate. 
Patients who were judged as having a dense lymphocytic infiltration were found to 
have improved suiwival compared to those gi'oups who had only moderate or scanty 
infiltration. However, patients within the cohort received a variety o f different 
treatments including radiotherapy, chemotherapy and androgen deprivation therapy 
during the course of follow-up. Irani and co-workers (1999) examined a cohort of
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161 men undergoing radical prostatectomy for localised prostate cancer. Prostatic 
tissue from each patient was examined and the degi'ee of tumour infiltration by 
inflammatory cells assessed. The inflammatory cell infiltrate was not separated by 
cell type (i.e. lymphocyte, monocyte, plasma cell or leukocyte). The specimen was 
classified as having high grade inflammation if there was evidence of inflammatory 
nodules, glandular epithelium dismption and interstitial inflammatory infiltrate. The 
specimen was considered to have low grade inflammation if none of these features 
were present. In contrast to the results of Vesalainen and co-workers, it was reported 
that patients who were assessed as having high grade inflammation had significantly 
higher rates of biochemical recuiTcnce than those with low grade inflammation.
Other studies have also reported a relationship between tumour infiltration by 
inflammatory cells other than lymphocytes and sui-vival. For example, it has been 
reported that scanty infiltration of the tumour by macrophages predicts poor prognosis 
(Shimura et al, 2000).
The role of a local cellular immune response to prostate cancers remains 
unclear. It seems logical that such an infiltrate would help control and even destroy 
tumour cells. However, it has been suggested that many of the lymphocytes found in 
tumour beds are inactive and therefore do not contribute to effective anti-tumoral 
immunity. Furthennore, the down-regulation of MHC II expression of some cancers, 
including prostate cancer, may help the tumour cells escape immune surveillance 
(Naoe et al, 2002). Elevations in PSA concentrations, normally associated with 
aggressive disease, have also been shown to have a direct immunosuppressive effect 
on T-lymphocyte function (Kennedy-Smith et al, 2002). Recently, it has also been 
reported that androgen deprivation induces a mai'ked cellular response in prostate 
cancer tissues. The reasons for this are not known but the authors suggest a number
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of possibilities. Firstly it is suggested that a mechanism may exist whereby the 
presence of androgens down-regulate the auto-immune response directed at prostatic 
tissue, thereby protecting prostate cancer cells fiom the immune system. Secondly, 
such a T-cell mediated response may be generated in response to androgen 
deprivation induced apoptosis rather than as direct anti-tumoral immunity (Mercader 
et al, 2001). Other studies have suggested that tumour-infiltrating lymphocytes may 
encourage disease progiession directly. For example, Freeman et al (1995) suggested 
that in some circumstances lymphocytes infiltrating prostate cancers produce 
angiogenic factors, such as vascular endothelial gi'owth factor, and thereby directly 
promote tumour growth and dissemination. In conclusion, the role of the cell- 
mediated immune response in patients with prostate cancer has not yet been 
established. Furthermore, the function of specific T-lymphocyte subsets in prostate 
cancer has not been evaluated.
2.0.2 The non-snecific inflamniatorv response
Any process, such as trauma, infection or malignancy, which results in cellular 
damage, can evoke a non-specific inflammatory response. This is a primitive yet 
essential innate host immune response to injury aimed at the restoration of tissue 
integrity. When activated, the non-specific inflammatory response triggers a cascade 
of physiological changes throughout the body which can involve many organ systems 
distant to the source of the inflammatory stimulus. This response is characterised by a 
complex series of non-specific responses, including fever, leucocytosis and 
breakdown of muscle protein. It also results in the dramatically increased synthesis 
and secretion o f a variety of plasma proteins (Bengmark, 2001). These proteins are 
known as the acute phase proteins. Indeed, this whole phenomenon was initially
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called the acute phase response. However, it was later discovered that this response 
often persisted in patients with cluonic infective or inflammatory disorders and in 
those with malignancy. As a result, it has been suggested that the term “systemic 
inflammatory response” is more accurate and should be used to avoid confusion 
(Gabay and Kushner, 1999).
The acute phase proteins are defined as proteins whose plasma concentrations 
increase, or decrease by a minimum of twenty-five percent as part of the systemic 
inflammatory response (Morley and Kuslmer, 1982). For example, the circulating 
concentrations of the complement proteins and clotting factors can increase by 50 to 
100 percent, whereas some of the proteinase inliibitors may increase several fold. 
Indeed, the most dynamic acute phase proteins, C-reactive protein and serum amyloid 
A, can change by more than thi'ee orders of magnitude (Figure 2.1). The changes in 
the circulating concentrations of the acute phase proteins result largely from changes 
in their production by hepatocytes. Regulation of the hepatic synthesis of the acute- 
phase proteins is controlled by a number of cytokines including tumour necrosis 
factor, interleukin-1 and interleukin-6. Although the concenti'ations of multiple 
components of the systemic inflammatory response commonly increase together, not 
all of them increase unifonnly in all patients with the same illness. This observation 
suggests that components of the systemic inflammatory response are individually 
regulated by specific cytokines.
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Figure 2.1 : Characteristic patterns of change in plasma concentrations of 
some acute phase proteins after a moderate inflammatory stimulus (Gabay and 
Kushner, 1999).
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The acute phase proteins
The systemic inflammatory response leads to the greatly enhanced synthesis of a 
number of plasma proteins along with a decrease in the plasma concentrations of 
some others. The major acute phase proteins are listed in Table 2.1. The role of the 
systemic inflammatory response is not fully understood but certain aspects appear to 
be of benefit to the individual. For example, increases in C-reactive protein and the 
complement proteins help eliminate infection, increased fibrinogen help prevent blood 
loss and protease inliibitors prevent excessive tissue necrosis when lysosomal 
enzymes are released by damaged cells.
65
Table 2.1: The major acute-phase proteins
Protein Types Increased Decreased
Proteinase inhibitors (X-antitrypsin
Coagulation proteins Fibrinogen 
Protlirombin 
Plasminogen 
Factor VIII
Complement Proteins Cl-5
C56
Properdin
Miscellaneous C-reactive protein Albumin
Serum Amyloid A HDL
Haptoglobulin LDL
Caeruloplasmin
Fibrinogen
The erythi'ocyte sedimentation rate (ESR) is defined as the rate at which red blood 
cells settle out of unclotted blood in one hour and is an indirect measurement of the 
circulating concentrations of fibrinogen. Fibrinogen is a soluble coagulation protein 
which can be converted by the enzyme tluombin to foim solid fibrin clot. Fibrinogen 
concentrations are usually elevated as part of the systemic inflammatory response.
The ESR is raised in many different conditions including infection, renal 
insufficiency, collagen diseases and malignancy. The ESR is also affected by 
physiological states such as age and pregnancy. This fact often makes interpretation 
of ESR results difficult. Furthennore, the ESR responds slowly to a stimulus and is 
slow to normalise after the stimulus has resolved. This means that ESR often does not 
accurately reflect disease activity at the time of sampling.
The complement proteins.
Consisting of a group of 20 plasma proteins, the complement system plays an 
important role in host defence against bacterial infections. The complement system 
can be activated by two independent pathways, called the classical and the alternative
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pathways. Activation of either of the complement pathways gives rise to the 
production of a membrane attack complex. This complex is extremely hydrophobic 
and has a high affinity for cell membranes. Binding between the membrane attack 
complex and a cellular membrane results in membrane disruption and cell lysis.
C-reactive protein.
A member of the pentraxin family of proteins, C-reactive protein (CRP) was first 
described by Tillet and Francis in the 1930’s, who noted its ability to bind to the C- 
polysaccharide component of the pneumococcal cell wall. Complexed or activated 
CRP was found to activate the complement pathway resulting in the opsonization and 
phagocytosis of bacteria or damaged cells. Since its discovery CRP has become 
established as a highly sensitive but non-specific marker of infection. Its synthesis in 
hepatocytes is induced by pro-inflammatory cytokines including tumour necrosis 
factor alpha (TNF-ce), interleukin-1 (IL-1) and interleukin-6 (IL-6) (Du Clos, 2000). 
The production of CRP increases rapidly within the first four hours o f exposure to the 
inflammatory stimulus and doubles every eight hours thereafter. The peak circulating 
concentrations of CRP occur approximately thirty-six to fifty hours after the onset of 
inflammation. The relatively short half-life o f CRP (approximately 19 hours) means 
that once the inflammatory stimulus has resolved, the circulating concentrations 
quickly return to normal. The rapid kinetics of CRP metabolism, which closely 
follow the inflammatory course make it the most useful clinical tool in measuring the 
course of inflammation-inducing disease processes. Although CRP has both pro and 
anti-inflammatory functions, its overall effect is anti-inflammatory because it prevents 
adhesion of neutrophils to the endothelial cells o f blood vessels, inhibits the 
production of oxygen free radicals and stimulates the production o f IL-1 receptors by 
mononuclear cells.
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Serum amyloid A
The serum amyloid A family consists of a number of differentially expressed 
apolipoproteins which are synthesised primarily by the liver. The serum amyloid A 
proteins are found tliroughout most vertebral species, implying an important generic 
role during inflammation. However, as yet the precise function of sei*um amyloid A is 
not fully understood. During the systemic inflammatory response the circulating 
concentrations of semm amyloid A may rise fi'om resting levels by 1000 fold (Uhlar 
and Whitehead, 1999). As with CRP, circulating levels of serum amyloid A fall 
rapidly with resolution of the inflammatory stimulus.
Albumin
Synthesised in the liver, albumin is the major plasma protein. It nomially accounts 
for around half of the hepatic protein production. Albumin has a long plasma half-life 
of around twenty days. During the systemic inflammatory response, albumin 
concentrations may fall. This phenomenon may be due to in part to nutritional 
depletion secondary to cytokine-induced anorexia. However, it is now recognised 
that albumin may also be catabolised along with skeletal muscle proteins to provide 
the amino acids required to support the increased production of other acute phase 
proteins.
The Cyclooxygenase enzymes.
The cyclooxygenases are enzymes involved in the conversion of arachidonic acid to 
prostaglandins and other eicosanoids. The cyclooxygenase (COX) enzymes mediate 
the conversion of arachidonic acid to prostaglandins by a two-step process. The first 
step involves the incoiporation of oxygen to arachidonic acid to form prostaglandin 
G2. The second step results in peroxidation of prostaglandin G2 to fonn
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prostaglandin H2, which in turn can be converted to a number of different 
prostaglandins. Oxygen free radicals are released as a by-product of these reactions 
(Kirschenbaum et al, 2001)
Two different isofonns o f the enzyme have been identified. The COX-1 
isofoiin is commonly expressed by a majority of mammalian cells and is involved in 
regulating water reabsorbtion, gastric acid production , blood flow and platelet 
aggregation. (Pairet and Engelhaidt, 1996). The COX-2 isoform, however, is induced 
by a variety of factors including cytokines such as IL-6, gi'owth factors and tumour 
promoters. COX-2 has been shown to be highly expressed in a number of human 
cancers and cancer cell-lines (Lee DW et al, 2002; Wu T, 2005; Liu J et al, 2005). 
Furthermore, over-expression of COX-2 has been linked to the promotion of 
carcinogenesis, resistance to apoptosis and abnormal cell cycle regulation.
Regulation of the systemic inflammatory response.
The systemic inflammatory response is regulated by cytokines. Cytokines are 
intracellular signalling polypeptides which are produced by cells activated in response 
to an inflammatory stimulus. The cytokines that are produced as part of the 
inflammatory response are the chief stimulators of the production of the acute phase 
proteins. These cytokines include tumour -necrosis factor, interleukin-6 (IL-6), 
Interleukin-1 (IL-1) and possibly interleukin-8 (IL-8). They are produced by a 
number of cell types, but the most important sources are macrophages and 
lymphocytes. In addition to stimulating the production of the acute-phase proteins, 
cytokines can also regulate the production of other cytokines. Furthennore, the 
effects of individual cytokines on target cells may also be affected by the presence of 
other cytokines, hi other words cytokines may enhance or inhibit the effects of other 
cytokines during an inflammatory response. Cytokines exert their influence on the
69
expression of the acute phase proteins by regulating transcription of the genes 
encoding these proteins (Gabay and Kushner, 1999)
Interleukin-1
Interleukin-1 is produced by macrophages and other nucleated cells in response to 
activation by contact with endotoxin, antigen or lymphokines such as interferon~7 . 
IL-1 triggers T-helper cell differentiation and the production of cytokines.
Interleukin-6
IL-6 belongs to the "IL-6 type cytokine family” which includes leukaemia inhibitory 
factor, IL-11, ciliary neurotropic factor, cardiotrophin-1 and oncostatin-M. In the 
normal homeostatic state, IL-6 levels are typically very low. However, in response to 
the appropriate stimulus (e.g. inflammation) a wide variety of cells can produce IL-6. 
Indeed, some adenocarcinoma cells have also been shown to secrete large quantities 
of IL-6. Many physiologic functions are attributed to IL-6 including promotion of 
antibody production from B-lymphocytes, induction o f thi'ombopoiesis, promotion of 
osteoclastic -mediated bone remodelling and modulation of acute-phase protein 
synthesis. Indeed, IL-6 is the chief regulator of production of most acute-phase 
proteins (Gauldie et al, 1987). High concentrations of IL-6 have been associated with 
fatigue, somnolence, depression, anorexia and day-time sleepiness. 11-6 mediates its 
activity, in part, through the IL-6 receptor complex (Corcoran and Costello, 2003).
Tumour-necrosis factor
TNF functions as a pyrogen, activates the clotting system, stimulates the hepatic 
production of the acute-phase proteins and over time can induce cachexia. TNF can 
be detected in malignant or human stromal cells in patients with ovarian, breast, 
prostate, bladder and colorectal cancers, hi malignant disease, high levels of TNF
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destroys tumour blood vessels. However, when chronically produced, TNF can act as 
an endogenous tumour promoter, contributing to the tissue remodelling necessary for 
tumour gi'owth and spread (Balkwell and Mantovani, 2001).
Inflammation and cancer
In 1863, Rudolf Virchow first suggested an association between inflammation and 
cancer. He hypothesised that leucocytes found in some malignant tissues were the 
origin of cancer. The evidence to support a link between inflammation and malignant 
disease has expanded over the last decade.
It is now recognised that approximately 15% of cancers worldwide are caused 
by an infectious agent (Balkwell and Mantovani, 2001). For example, ceiwical and 
penile cancers are associated with the human papilloma vims, hepatocellular 
carcinoma is caused by hepatitis B and C and gastric cancer is linked to H-pylori 
infection. Furthermore, some cancers have also been associated with chionic 
inflammation caused by chemical and physical elements. For example, mesothelioma 
is related to asbestos exposure, bronchial carcinomas to smoking and skin cancers to 
ultra violet light. Recently, there have also been a number of studies which indirectly 
implicate inflammation in the development of cancer. It has been shown that people 
who take non steroidal anti-inflammatory dmgs (NSAIDS) have a reduced risk of 
developing colorectal cancer (Thun et al, 1993). There is also evidence to suggest 
that the use of NSAID’s reduces the risk of developing a number of other cancers 
including breast, bladder, stomach and prostate.
It is not clear how inflammation facilitates the development o f malignancy, 
but several potential mechanisms have been proposed (Balkwell and Mantovani,
2001). It is thought that oxygen radicals generated by inflammation can oxidise 
DNA, resulting in mutagenic changes and damage to the DNA repair proteins.
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Another link between inflammatory cytokines and DNA damage come from studies 
examining the regulation of the tumour suppressor gene p53 (Hudson et al, 1999). It 
has been suggested that some cytokines may be able to inactivate p53, thus increasing 
cellular proliferation and inlhbiting apoptosis of potential tumour cells. In addition to 
inhibiting apoptosis, it has also been shown that many cytokines have the potential to 
directly stimulate tumour cell proliferation by acting as autocrine growth factors.
Once a malignancy is established it needs to secure an adequate blood supply 
to allow gi'owth and metastasis. It is thought that some proinflammatory cytokines, 
such as TNF and IL-6, can promote tumour angiogenesis by stimulating the 
production of angiogenic factors such as vascular endothelial growth factor (VEGF). 
Cytokines may also encourage metastatic spread by acting as chemokines. Many 
tumour types express cellular adhesion molecules and it is thought that cytokines may 
promote migration and the use of these cellular adhesion molecules to seed cancer 
cells to distant anatomical sites.
Most malignant tumours, especially when extensive or metastatic, induce a 
systemic inflammatory response. This is particularly pronounced with those 
malignancies, such as renal cell carcinoma, which may produce systemic symptoms 
such as fever and weight loss. Indeed, markers of the systemic inflammatory 
response such as CRP have been shown to provide useful predictors of extent of 
disease, disease recuiTence and suiwival in a variety of common solid tumours. 
Furthermore, CRP has been shown to be useful in monitoring progression and 
regies si on of some tumour types,
CRP and suiwival in patients with cancer.
The impact of the presence of a systemic inflammatory response, as evidenced by 
elevated circulating concentrations of CRP, on patient survival has been examined in
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number o f different malignancies. C-reactive protein has been shown to predict 
suiwival in a number of tumour types including renal (Ljungberg et al, 1995), 
melanoma (Tartour et al, 1994), lymphoma (Legouffe et al, 1998) and ovarian 
carcinoma (Kodama et al, 1999). Colorectal cancer is, however, the most widely 
studied model for assessing the impact of the systemic inflammatory response on 
siu-vival. Indeed, there is increasing evidence to support the hypothesis that raised 
pre-operative or post-operative circulating C-reactive protein concentrations correlate 
with poor survival in patients with colorectal cancer, independent o f stage (McMillan 
et al, 1995; Nozoe et al, 1998, Nielsen et al, 2000)
The systemic inflammatory response and cancer cachexia.
Cancer cachexia is one of the most debilitating conditions associated with advanced 
malignancy and has a significant impact on quality of life and survival. It has been 
estimated that 20% of patients with advanced cancers die directly as a result of 
cachexia rather than tumour burden (Argiles et al, 2001). Cachexia is a metabolic 
condition characterised by weight-loss and anorexia and the depletion of adipose 
tissue and skeletal muscle. Cachexia has been shown to be related to the presence of 
a systemic inflammatory response in a number of studies (Barber et al, 1999). There 
are a number of possible ways by which the systemic inflammatory response may 
produce the cancer cachexia syndrome. The experimental administration of cytokines 
such as TNF-O! induces many of the metabolic features o f cachexia (Wan*en et al,
1987). In particular the presence of pro-inflammatory cytokines is associated with 
skeletal muscle breakdown and loss of lean body cell mass. Moreover, the presence 
of the prolonged acute phase protein response often seen in patients with advanced 
cancer can contribute to cachexia. The ongoing production of acute phase proteins 
such as CRP is thought to result in reprioritising of amino-acid use away from
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peripheral tissues, such as muscle, in favour of the liver where the acute phase 
proteins are produced. It is now generally accepted that cachexia is not reversed by 
nutritional supplementation alone. However, it is of great interest that recent studies 
have suggested that modulation of the systemic inflammatory response through the 
use of NSAIDs can reverse weight loss and improve quality of life in weight losing 
cancer patients (McMillan et al, 1999)
The cyclooxygenase enzymes and cancer.
It is thought that the COX enzymes may contribute directly to the carcinogenic 
process tlu'ough the production of oxygen free radicals which results in DNA damage. 
Furthermore, some prostaglandin H2 is converted to malondialdehyde which is also 
known to stimulate mutagenic changes in DNA (Kirschenbaum et al, 2001). It is 
therefore of interest that patients taking non-steroidal anti-inflammatory drugs, which 
inhibit the actions of the COX enzymes, are at reduced risk of developing some 
cancers such as cancer o f the colon (Samoha and A lter, 2005) and breast (Xu XC, 
2002).
Besides initiating carcinogenesis, there is evidence to suggest that the 
cyclooxygenase enzymes may also be implicated in promoting tumour growth and 
dissemination. For example, there is growing evidence to suggest that in a number of 
tumour types, prostaglandins may have a role in protecting tumour cells fi'om 
undergoing apoptosis and therefore encourage tumour giowth. It is therefore of 
interest that several studies have demonstrated that non-steroidal anti-inflammatory 
drugs, which inhibit the production of prostaglandins, induce apoptosis in a number of 
tumour types, including prostate cancer cells (Liu XH et al, 1998). There is also 
evidence that COX-2 may promote disease progression and dissemination in cancer 
patients. For example, in many tumour types, such as breast cancer, COX-2
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expression has been strongly associated with expression of vascular endothelial 
growth factor (VEGF) (Timoshenko et al, 2006). This pro-angiogenic factor is known 
to promote neovascularisation and thus facilitate tumour growth and spread of tumour 
cells. It has also been postulated that the production of prostaglandins may result in 
apoptosis of immune cells such as natural killer cells. This in turn may allow tumour 
cells to gi'ow and disseminate whilst escaping from immune surveillance mechanisms 
(Myers et al, 2001).
The systemic inflammatory response in prostate cancer.
For many years clinicians have sought prognostic markers which would help 
distinguish between prostate cancers with good prognosis and those which were likely 
to progi ess. This is of importance in patients with prostate cancer as treatment often 
canied significant morbidity and there was concern that some patients may be 
unnecessarily treated. It was in this context that the first studies examining the 
relationship between the systemic inflammatory response and prostate cancer were 
performed. For example, Johansson and colleagues (1992) reported that raised ESR 
levels were associated with disease progression in patients with prostate cancer. The 
prognostic value of ESR was later shown to be independent of PSA (Bon e et al,
1997). Furthermore, Trautner and colleagues (1980) reported that elevations in 
circulating CRP concentration were associated with disease progression in patients 
receiving oestrogen therapy. The presence of abnormal cytokine levels has also been 
associated with increased stage and disease progression. For example, Adler and co­
workers (1999) reported significantly higher IL-6 concentrations in patients with 
metastatic prostate cancer. These results were later confirmed by Shariat and 
colleagues (2001). It has also been reported that patients with hoiinone-escaped 
prostate cancer had significantly higher levels of IL-6 than patients with homione
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sensitive disease (Wise et al, 2000). It has been suggested that IL-6 may participate 
directly in disease progression by acting as a growth factor (Okamoto et al, 1997) and 
by inhibiting apoptosis (Chung et al, 2000),
Cancer cachexia is of particular importance in patients with prostate cancer. It 
has been estimated that approximately 60-70% of patients with advanced prostate 
cancer suffer and die from cachexia (Ai’giles et al, 2001). As with other tumour types, 
the basis of cachexia in advanced prostate cancer patients appears to be multi-factorial 
and is poorly understood. However, several cytokines including IL-1, IL-6, TNF-a 
and IL-8 have been implicated as agents responsible for the features of cachexia. For 
example, Nakashima and colleagues (1998) reported that TNF-cx contributed to the 
complex syndrome of cachexia in patients with prostate cancer. Furthermore, 
Pfitzenmaier and co-workers (2003) demonstrated that several cytokines including 
TNF-O, IL-6 and IL-8 were elevated in patients with advanced prostate cancer 
suffering from cachexia when compared with patients who were without cachexia.
The cyclooxygenase enzymes and prostate cancer
It is now widely accepted that the COX enzymes, and in particular COX-2, have an 
important role to play in carcinogenesis and disease progiession in many tumour 
types.
Weak expression of both the COX isofonns has been reported in nornial 
prostate tissue and benign prostatic hyperplasia (Yoshimura et al, 2000). Indeed, 
Madaan and colleagues (2000) reported that COX-1 appeared to be equally expressed 
in both cancer and benign tissue. There was, however, a significant over expression 
of COX-2 in prostate cancer tissue when compared with benign controls. The authors 
also found a significant coiTelation between increasing tumour grade and COX-2 
expression. This suggests that COX-2 expression is related to a malignant phenotype.
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Tjandrawinata and Hiiges-Fulford (1997) reported that increased prostaglandin 
synthesis has giowth-promoting and positive feedback effects in prostate cancer. For 
example, they found that cellular proliferation rates increased in prostate cancer cells 
treated with exogenous prostaglandins. Furthennore, they found that prostaglandins 
increased COX-2 expression, and that this resulted in further prostaglandin production 
via a positive feedback loop. COX-2 is also reported to promote tumour growth by 
inliibiting apoptosis of prostate cancer cells (Liu et al, 2005).
The cyclooxygenases may also be involved in dissemination of tumour cells 
by encouraging angiogenesis. For example, Wang and colleagues (2005) reported 
that angiogenesis, as measured by microvessel density, is increased in prostate cancer 
tissue expressing COX-2. Interestingly, the authors also reported that COX-2 
expression is increased in tissue infiltrated by inflammatory cells such as T- 
lymphocytes. It is thought that cytokines, such as IL-6, produced by lymphocytes and 
other inflammatory cells induce the expression of COX-2.
It is therefore of interest that several epidemiological studies have 
demonstrated a reduction in the risk of developing prostate cancer in men taking 
regular non-steroidal anti inflammatory drugs (NSAIDs). For example, Nelson and 
Hams (2000) reported a 66% reduction in the risk of developing prostate cancer in 
men taking daily doses o f aspirin or ibruprofen. Another study found a lower 
incidence of prostate cancer in men over the age of sixty who regularly consumed 
NSAIDs compared to age-matched controls in the general population (Roberts et al,
2002). Norrish and colleagues (1998) have also reported a trend towards a reduction 
in risk of advanced prostate cancer following the regular administration of aspirin.
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3.1.0 The relationship between T-lymphocyte snbset infiltration and survival in 
patients with prostate cancer.
3.1 Introduction
It has long been recognised that disease progression in cancer patients is not solely 
determined by the characteristics of the tumour but also by the host response. Indeed 
there is increasing evidence that both local and systemic inflammatory responses play 
an important role in the progression of a variety of common solid tumours (Coussens 
and Werb, 2002).
For example, in patients with colorectal cancer, there is good evidence that the 
presence of a pronounced lymphocytic infiltration within the tumour is associated 
with improved survival (Jass et ah, 1987; Ropponen et ah, 1997, Nielsen et ah, 2000). 
More recently, the ability to identify lymphocyte subsets has led to renewed interest in 
the relationship between the tumour inflammatory infiltrate and outcome. Indeed, 
increased infiltration of the tumour by CD8+ and CD4+ T-lymphocytes has been 
shown to be associated with increased suiwival in patients with colorectal cancer 
(Niato et ah, 1998; Ali et ah, 2004). In contrast, the presence of an increased 
infiltration by CD4+ or CD8+ T-lymphocytes has been associated with decreased 
survival in patients with renal cancer (Nakano et al 2001, Bromwich et al 2003).
The relationship between lymphocytic infiltration and suiwival in other 
urological cancers, for example prostate cancer, is less clear. Indeed, at the time that 
this work was canied out, only two papers had been published in a peer-reviewed 
journal. Vesalainen and coworkers (1994) reported that, in a cohort in which 
approximately 30% of patients had metastatic disease, tumours with a dense tumour
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lymphocyte infiltration were associated with higher survival rates than tumours with 
absent or decreased infiltrates. In contrast, Irani and his co-workers (1999) reported 
that, in patients imdergoing radical prostectomy, an increased inflammatory cell 
infiltrate within the tumour was associated with an increased risk of tumour 
recurrence.
To date, the relationship between lymphocyte subset infiltration and survival 
does not appear to have been assessed in patients with prostate cancer. The aim of the 
present study was to examine the relationship between CD4+ and CD8+ T- 
lymphocyte infiltration and suiwival in patients with prostate cancer.
3.2 Patients and Methods
Patients
Patients who underwent radical local treatment for histologically proven prostate 
cancer (n= 11) or who were diagnosed as having prostate cancer following 
transurethral resection o f prostate for bladder outflow obstruction (n= 69) were 
included in the study. Clinical details recorded included age, stage, tumour grade, 
circulating concentrations of PSA and haemoglobin at diagnosis and subsequent 
treatment.
All patients were followed up in the Department of Urology. The date and 
cause of death was obtained fr om the cancer registry.
The study was approved by the local ethics committee.
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Methods
Immunohistochemistry: Blocks from the primary tumour were fixed in 10% 
buffered fonnalin and embedded in paraffin wax. One representative block of tumour 
was selected fi'om each patient. Sections (4 pm) were cut and mounted on slides 
coated with aminopropyltriethoxysilane.
Sections were then immunostained using the peroxidase-based Envision 
(Dako, Cambridgeshire, UK) technique as previously described (Bromwich et al.,
2003). The primary antibody for CD4 was mouse monoclonal (Vector, Peterborough, 
UK) and that for CDS was mouse monoclonal (Dako, Cambridgeshire, UK). Sections 
were dewaxed and rehydrated. Endogenous peroxidase was blocked by incubation in 
0.3% hydrogen eroxide for 10 minutes. Antigen retrieval for CDS was performed by 
micro-waving in ImM EDTA buffer, pH 8 for 5 minutes at full pressure in a plastic 
pressure cooker in a microwave oven. Antigen retrieval for CD4 was achieved by 
immersing the sections in high pH buffer (9.9 Dako) in a coplin jar, maintained at 
99°C for 75 minutes in a water bath.
The sections were then incubated with the primary antibodies at dilutions of 
1:50 (CD4) and 1:100 (CDS) for 30 minutes at room temperature. Sites of binding 
were detected using the Envision kit with 3 '3 ' diaminobenzidine as cliromogen 
according to the manufacturers instmctions. Sections were counterstained with 
haematoxylin, dehydrated, cleared and mounted with Pertex.
Formalin fixed tonsil was included in each run as a positive control. The 
negative control for each case was the omission of the primary antibody. Examples of 
the immunohistochemical staining for CD4+ and CD8+ lymphocytes are provided in 
figures 3.1 and 3.2.
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Figure 3.1 Example of the immunohistochemical staining for CD4+ lymphocytes in 
prostate cancer.
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Figure 3.2 Example of the immunohistochemical staining for CD8+ lymphocytes in 
prostate cancer.
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Morphometry: Quantitative analysis of the lymphoid infiltrate was performed using 
point counting (Anderson and Duimill, 1965) with a random sampling teclmique.
With this method, the volume occupied by any given component (volume density) is 
expressed as a percentage of the total volume of the tissue. A 100-point ocular grid 
was used at X400 magnification and 30 fields were counted per case for CD4+ and 
CD8+ immunopositive cells. Only fields within the tumour (including cancer cell 
nests and surrounding tissue stroma) were counted. Any normal tissue on the slide 
was excluded from the analysis.
This final method was designed on the basis of a pilot study, which 
demonstrated that the volume density of CD4+ and CD8+ of two obseiwers reached a 
plateau after 25-30 fields. This pilot study also demonstrated that CD4+ and CD8+ 
counts were equivalent to the CD3+ counts (Ali et al, 2004). The obseiwers (McAi’dle 
and Camra) were blinded to the clinical outcome of the patient.
Statistics
Data are presented as median and range. Where appropriate, comparison of patient 
gi'oups was carried out using contingency table analysis (X^) and the Kruskal-Wallis 
test for analysis of variance. For the puipose of survival analysis T-lymphocyte 
subset counts were grouped into tertiles as previously described (Nielsen et al., 1999). 
Suiwival analysis was performed using the Cox proportional hazard model. Deaths up 
to August 2003 have been included in the analysis. Analysis was performed using 
SPSS software (SPSS Inc., Chicago, Illinois, U.S.A.).
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3.3 Results
Eighty patients were included in the study. The baseline characteristics, according to 
stage, are shown in Table 3.1 Patients with metastatic disease were older (p<0.05), 
had higher circulating concentrations o f PSA (p<0.001) and had lower haemoglobin 
(p<0.05) concentrations. Twenty one patients undement radical local therapy 
(prostatectomy or radical radiotherapy) as primary treatment. The remaining 59 
patients received andi'ogen deprivation therapy. The median (range) for percentage 
volume of CD4+ T-lymphocytes was 0.40 (0.03-1.90). The median (range) for 
percentage volume of CD8+ T-lymphocytes was 0.78 (0.27-3.00). More patients with 
metastatic disease died o f prostate cancer
The baseline characteristics, according to PSA concentration, are shown in 
Table 3.2. Patients with higher PSA concentrations had more advanced disease 
(p<0.001), had higher grade tumours (p<0.05) and were more likely to die of their 
diease (p<0.05).
The baseline characteristics, according to tumour CD4+ T-lymphocytic 
infiltration (tertiles 1, 2, 3), are shown in Table 3.3. There were no significant 
associations with increasing CD4+ T-lymphocytic infiltration.
The minimum follow-up was 26 months; the median follow-up of survivors 
was 71 months. Forty-one patients died during follow-up, 22 of prostate cancer and 
19 of intercuiTent disease. The mean cancer specific-sui'vival for those with localised, 
locally advanced and metastatic disease was 120, 98, and 66 months respectively
(p=0,001).
On univariate analysis, advanced stage (p<0.01), elevated PSA concentrations 
(p<0.01), decreased haemoglobin (p<0.05) and increased CD4+ T-lymphocyte counts
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(p<0.05) were associated with reduced cancer specific survival (Table 3.4). On 
multivariate analysis PSA (HR 2.47, 95%CI 1.27-4.83, p-0.008), haemoglobin (HR 
3.48, 95%CI 1.30-9.30, p=0.013) and CD4+ T-lymphocyte count (HR 2.29, 95%CI 
1-25-4.22, p=0.008) retained independent significance. There was no significant 
correlation between PSA concentrations and either CD4+ (p=0.539) or CD8+ 
(p=0.202) T-lymphocytes.
When those patients with localised or locally advanced prostate cancer (n=57) 
were examined in univariate analysis, only CD4+ T-lymphocyte count achieved 
statistical significance (HR 2.88, 95%CI 1.15-7.22, p=0.024).
3.4 Discussion
The results o f the present study show that the presence of an increase in CD4+ T- 
lymphocyte infiltrate was associated with poor cancer specific suiwival, independent 
of stage, in patients with prostate cancer. Furthermore, when the analysis was 
confined to those patients with localised or locally advanced disease, only CD4+ T- 
lymphocyte count predicted survival. These results are consistent with those of Irani 
and coworkers (1999) but not with those of Vesalainen and coworkers (1994).
The reasons for the difference in the results of the present study and those of 
Vesalainen and coworkers (1994) are not clear. Both cohorts included a wide 
spectrum of disease and both had a similar proportion of patients with metastatic 
disease. However, the apparent discrepancies may reflect differences in methodology 
including the way in which the inflammatory infiltrate was assessed.
Vesalainen and his colleagues studied a heterogeneous group of 325 patients 
with prostate cancer, o f whom 101 had metastatic disease at the time of diagnosis.
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The majority of patients received at least fomi of treatment, mainly in the form of 
oestrogens or an orchidectomy. However, it is not clear whether any of the patients in 
this cohort had received treatment prior to tissue sampling. Potentially this is a 
confounding factor since it is now known that androgen withdrawal is associated with 
an increase in tumour infiltrating lymphocytes (Mereader et al, 2001).
Tissue samples obtained from surgical or needle specimens were studied.
Since only eight patients underwent a radical prostatectomy, it is likely that the 
majority of tissue samples were collected from a “needle biopsy”. It is not clear 
whether the “needle biopsies” were obtained by a tm-cut biopsy or fme-needle 
aspiration. In the case of a tm-cut biopsy, only a small afriount of tissue is removed 
and this may not be representative of the tumour as a whole. In the latter case, 
although it is possible to harvest tumour cells and lymphocytes, the normal tissue 
architecture is lost.
The density of tumour infiltrating lymphocytes was assessed on simple 
staining with haematoxylin and eosin. The type of lymphocyte was not assessed. A 
pronounced lymphocytic infiltration of the primary tumour was found to be associated 
with improved suiwival.
In contrast Irani and colleagues, evaluated a cohort of 161 men undergoing 
radical prostatectomy for localised prostate cancer. None of the patients had nodal 
involvement; none had received any treatment prior to surgery. Prostatic tissue fiom 
each patient was examined and the degree of tumour infiltration by inflammatory cells 
assessed. The inflammatory cell infiltrate was not separated by cell type (i.e. 
lymphocyte, monocyte, plasma cell or leukocyte). The specimen was classified as 
having high gi*ade inflammation if there was evidence of inflammatory nodules, 
glandular epithelium disruption and interstitial inflammatory infiltrate. The specimen
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was considered to have low grade inflammation if none of these features were present. 
The authors reported that patients who were assessed as having high giade 
inflammation had significantly higher rates of biochemical recurrence than those with 
low grade inflammation. Furthermore, this effect was found to be independent of 
Gleason score, pre-operative PSA and pathological stage.
In the present study, none of the patients had received treatment prior to 
surgery. T-lymphocyte subsets were identified by immunohistochemistry and the 
density was assessed using a point counting teclmique. This approach provided a 
more objective assessment and circumvented the problem of variation in distribution 
of lymphocytes within an individual tumour.
High CD4+ T-lymphocyte counts were associated with reduced cancer 
specific survival. This effect was independent of pre-operative circulating PSA 
concentrations.
In view of the apparent differences in the relationship between lymphocytic 
infiltration and outcome in the different studies, it is of paiticular interest that, since 
our work has been published, a further paper from the original institution has been 
published (Karja et al, 2005). One hundred and eighty-eight patients undergoing 
radical prostatectomy were evaluated. Immunohistochemistry was used to assess the 
degree o f lymphocytic infiltration. Low levels of lymphocytic infiltration within the 
tumour were found to be associated with organ confined disease, whilst strong 
lymphocytic infiltration was associated with perineural invasion, capsular invasion 
and shortened biochemical recun'ence free survival.
Why the presence of an increase in CD4+ T-lymphocyte infiltrate would be 
associated with poor cancer specific suiwival in patients with prostate cancer is 
unclear since it would seem logical that an increased T-lymphocyte infiltrate would
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help control and even destroy tumour cells. However, it has been suggested that 
many of the T-lymphocytes found in tumour beds are inactive and therefore do not 
contribute to effective anti-tumoral immunity. Indeed, this concept is consistent with 
the observation that downregulation of MHC I expression may help tumours cells 
escape immune surveillance (Naoe et al., 2002).
In summary, the results o f the present study have shown that the presence of 
increased CD4+ T-lymphocyte infiltration within the tumour was associated with 
poor outcome, independent of stage and PSA, in patients with prostate cancer.
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Table 3.4. Clinicopatho logic al characteristics 
univariate survival analysis.
in patients with prostate cancer:
Patients Hazard ratio p-value
(n= 80) (95% Cl)
Age gi'oup (<70/ >70) 38/ 42 2.38 (0.97-5.85) 0.059
Stage
(localised/ locally advanced/ metastatic) 20/ 37/ 23 2.99 (1.52-5.88) 0.002
Tumour grade (low/ intermediate/ high) 18/36/ 26 1.41 (0.80-2.51) 0.238
PSA (<4/ 4-10/ 11-100/ >100 ng/ml) 11/12/41/13 2.50(1.38-4.52) 0.002
Haemoglobin (>12/ <12 g/1) 61/14 3.38 (1.28-8.90) 0.014
Tumour counts
CD4+ T-lymphocyte count (tertiles) 26/ 28/ 26 2.03 (1.15-3.59) 0.015
CD8+ T-lymphocyte count (tertiles) 26/ 28/ 26 1.46 (0.85-2.52) 0.170
CD4+ plus CD8+ count (tertiles) 26/ 28/ 26 1.69 (0.97-2.97) 0.065
Treatment
(radical local/ androgen deprivation) 21/59 2.08 (0.70-6.17) 0.188
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4.1.0 The systemic inflammatory response and survival in patients with
metastatic prostate cancer
4.1 Introduction
Prostate cancer is the second commonest cause of death from cancer in men in the 
UK. Each year there are more than 10,000 deaths fi'om the disease and prostate 
cancer accounts for 13% of all deaths from cancer in men. Overall sui*vival is 
approximately 60% at 5 years (Cancerstats 2002; www.cancerresearchuk.org).
At presentation, there are a number of tumour-based factors, which can be 
used to predict the extent of disease and therefore survival in patients with prostate 
cancer. These include clinical stage, tumour grade and circulating concentration of 
prostate specific antigen (PSA). Furthennore, the value of PSA as a predictor of 
suiwival in patients with metastatic disease is well established.
However, it is increasingly recognised that, in cancer patients, disease 
progression is dependent on a complex interaction of the tumour and the host 
inflammatory response (Balkwill and Mantovani, 2001; Coussens and Werb, 2002).
It is therefore of interest that the presence of a systemic inflammatory response, as 
evidenced by elevated circulating concentrations of C-reactive protein, has been 
shown to be an independent predictor of suiwival in patients with advanced 
gastrointestinal, lung and renal cancer (O'Gorman et ah, 2000; Scott et ah, 2002; 
Bromwich et al, 2003).
The aim of the present study was examine the relationship between the 
systemic inflammatory response, PSA and survival in patients with metastatic prostate 
cancer.
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4.2 Patients and methods
Patients with metastatic prostate cancer attending hospitals in the North Glasgow 
NHS Trust between January 1997 and December 2002 were included in the study.
All patients had histologically proven prostate cancer and had radiologically 
confirmed metastatic disease. All patients had been established on androgen 
deprivation therapy. Some patients had previously been treated with radiotherapy. A 
blood sample was taken for the measurement of total PSA and C-reactive protein. At 
this time no patient showed clinical evidence of infection or other inflammatory 
condition.
The study was approved by the Research Ethics Committee of the North 
Glasgow NHS Trust.
Total PSA was measured using the Bayer ADVIA Centaur Assay system 
(Bayer PLC, Bayer House, Newbury, UK). Inter-assay variability was <6% for total 
PSA.
C-reactive protein was measured by Fluorescence Polarisation Immunoassay 
using an Abbott TDX analyser and Abbott reagents Abbott Laboratories, Abbott Park, 
IL, USA). The limit of detection of the assay is a C-reactive protein concentration of 
less than 5mg/l. The coefficient of variation, over the range of measurement, was less 
than 5% as established by routine quality control procedures.
Statistics
Based on previous work (O’Goiman et al., 2000), a C-reactive protein 
concentration greater than lOmg/1 was considered to indicate the presence of a
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systemic inflammatory response. Univariate survival analysis was performed using 
the Kaplan-Meier method. Multivariate survival analysis and calculation of hazard 
ratios (HR) were performed using the Cox regression analysis with prognostic scores 
as covariates. Deaths up to June 2005 were included in the analysis. Analysis was 
performed using SPSS software (SPSS hic., Chicago, IL, USA).
4.3 Results
The baseline characteristics of the patients with metastatic prostate cancer (n= 62) are 
shown in Table 4.1. The majority of patients were aged over 70 years and had 
intermediate or high-grade tumours. Approximately half the patients had a PSA 
greater than lOng/ml and a third had an elevated circulating C-reactive protein 
concentration. Fifty one patients had received androgen deprivation therapy alone 
and 11 had received a combination of androgen deprivation therapy and radiotherapy.
In all, 41 (66%) o f patients died, 38 (61%) of their disease during the follow- 
up period. The median follow-up of the survivors was 62 months. On univariate 
sui-vival analysis, PSA (p<0.05. Figure 4.1) and C-reactive protein (p<0.05. Figure 
4.2) were significant predictors o f cancer specific survival. On multivariate analysis, 
both PSA (HR 1.96, 95%CI 1.00-3.83, p=0.049) and C-reactive protein (HR 1.97, 
95% Cl 0.99-3.92, p=0.052) were predictors of cancer specific survival. PSA 
concentrations were significantly correlated with those of C-reactive protein (i's= 0.46,
p<0.001).
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4.4 Discussion
The results of the present cross-sectional study show that, in patients with metastatic 
prostate cancer, both an elevated circulating PSA concentration and the presence of a 
systemic inflammatory response, as evidenced by an elevated C-reactive protein 
concentration, were associated with poorer cancer specific sui*vival. Furthennore, on 
multivariate analysis, the prognostic value of both was similar and both were 
significantly correlated. These results would suggest that the systemic inflammatory 
response is associated with disease progression. However, it remains to be 
determined whether an elevated C-reactive protein will provide useful additional 
prognostic information.
Few studies have examined the role C-reactive protein as a prognostic factor 
in prostate cancer. Trautner and co-workers (1980) reported that, in a cohort of 102 
patients including 31 patients with metastatic disease, the rise in C-reactive protein 
concentrations was associated with tumour progression even when the patient was 
receiving oestrogen therapy. Lewenhaupt and co-workers (1990) also reported that, 
in a cohort of patients including 31 (30%) patients with metastatic disease, an elevated 
C-reactive protein concentration was associated with suiwival on univariate analysis 
but not on multivariate analysis. However, the above studies included patients with 
localised disease who were unlikely to progress and patients with metastatic disease 
who had already progressed. This is likely to have confounded the assessment of the 
prognostic value of an elevated circulating C-reactive protein concentration.
The mechanism by which a systemic inflammatory response might impact on 
cancer-specific siuTival is not clear. There is evidence to suggest that interleukin-6, 
which is lai-gely responsible for the production of C-reactive protein (Ljungberg et
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al, 1997; McAi'dle et al, 2004; McKeown et al., 2004) can be produced by pro static 
tumours (Corcoran et al, 2003). Furthermore, increased circulating concentrations of 
interleukin-6 have been shown to be associated with reduced survival in patients with 
piostate cancer (Nakashima et al, 2000). Interleukin-6 has also been shown to act as 
an autocrine growth factor (Okamoto et al, 1997; Lou et al, 2000) and to inhibit 
apoptosis in prostate cancer (Chung et al, 2000). However, it is not clear whether 
interleukin-6 is superior to C-reactive protein in predicting survival in patients with 
metastatic prostate cancer.
In summary, the results of the present study suggest that, in patients with 
metastatic prostate cancer, the presence of a systemic inflammatory response during 
the follow-up period may predict poor outcome, independent of PSA.
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Table 4.1. The characteristics of patients with metastatic prostate cancer. Univariate 
sui-vival analysis performed using the Kaplan-Meier method with log-rank test.
Age <70yi's 
>70 yrs 
Gleeson score 2-6 
7
8-10
PSA <10 ng/ml 
>10 ng/ml 
C-reactive protein <10mg/l 
>10mg/l
Patients 
62 (%) 
27 (44) 
35 (56) 
17(27) 
19(31) 
17(27) 
33 (53) 
29 (47) 
43 (69) 
19(31)
Survival (months) p-value
Mean (95%CI)
52.6 (40.8-64.5)
38.5 (28.5-48.5) 0.132
51.9 (36.7-67.1)
39.8 (26.9-52.7)
37.4 (23.5-51.3) 0.301
53.4 (43.8-62.9)
3.4.7 (23.1-46.3) 0.012
51.8 (42.8-60.8)
30.2 (16.2-44.1) 0.010
Treatment 
Androgen deprivation 
Combination therapy
51 (82) 
11(18)
44.9 (36.5-53.3)
41.8 (22.4-61.2) 0.639
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Figure 4.1. The relationship between PSA (<10/ >10ng/ml from top to bottom) and 
cancer specific survival in patients with metastatic prostate cancer (n=62).
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Figure 4.2. The relationship between C-reactive protein (<10/ >10mg/l fi-om top to 
bottom) and cancer specific survival in patients with metastatic prostate cancer 
(11=62).
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5.0.1 The relationship between interleukin-6 and C-reactive protein in patients 
with benign and malignant prostate disease
5.1 Introduction
The systemic inflammatory response is an obligatory response o f the body to 
infection, surgery or trauma. There is also increasing evidence that the presence of a 
systemic inflammatory response, as evidenced by increased circulating concentrations 
of C-reactive protein, is associated with early recurrence and poor survival in a variety 
of common hoi*mone independent tumours (Nielsen et al., 2000; Scott et al., 2002; 
McMillan et al., 2003). There is also some evidence that a similar relationship exists 
in hoimone dependent tumours (Lewenhaupt et al., 1990; Alberquerque et al., 1995).
A number of factors appear to mediate the increased production of C-reactive 
protein. In injury, the pro-inflammatory cytokines, interleukin-1, TNT-alpha and 
interleukin-6 in particular, have been shown to stimulate the production of C-reactive 
protein (Gabay and Kushner, 1999). In cancer, the factors which determine 
circulating concentrations of C-reactive protein are less clear since studies in cell lines 
and animal tumour models have demonstrated that a number of factors stimulate C- 
reactive protein production. For example, it has been shown that leukaemia inhibitory 
factor and ciliary neurotrophic factor are also capable of inducing an acute phase 
protein response fi-om the liver (Baumann et al 1993, Henderson et al 1994, Akiyama 
et al 1997). There is also evidence that soluble receptor subunits involved in 
interleukin-6 signal transduction, the soluble interleukin-6 receptor and the soluble 
gpl30 receptor, may be important in the regulation of interleukin-6 activity and the 
acute phase protein response (Narazaki et al., 1993; Jones et al., 2002). Therefore, if
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in cancer patients, C-reactive protein was stimulated by factors other than interleukin- 
6 then it might be expected that the relationship between interleukin-6 and C-reactive
'(^  . .^p'rotein wouldjjess strong than that in patients with benign disease.
The aim of the present study was to examine the relationship between 
interleukin-6 and C-reactive protein in patients with benign disease (BPH) and in 
prostate cancer.
5.2 Patients and methods
Consecutive patients undergoing diagnostic transrectal ultrasound guided (TRUS) 
biopsy of prostate were included in the study. The indication for TRUS biopsy was 
either a total PSA concentration greater than 4ng/mL and/or an abnormal digital rectal 
examination.
Prior to biopsy, a blood sample was obtained and the semm stored at -20°C 
prior to analysis. No patient had a digital rectal examination within a two-week 
period prior to sampling. No patients were taking non-steroidal anti-inflammatory 
drugs or were receiving treatment for prostate cancer at the time of blood sampling.
None of the patients had participated in a fonnal screening progi'amme. All 
patients underwent a minimum of systematic sextant biopsy. A Gleason score was 
allocated for each tumour. The Gleason score reflects tumour heterogeneity by 
combining primary and secondary patterns into a composite score which has been 
shown has been shown to be an important predictor of disease recurrence and survival 
(Epstein et al., 1993). Gleason scores were compressed as previously recommended 
(Bostwick et al., 2000).
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The study was approved by the local Research Ethics Committee. All subjects 
were informed of the purpose and procedure of the study and all gave written consent.
Total PSA was measured using the Bayer ADVIA Centaur Assay system 
(Bayer PLC, Bayer House, Newbury, UK). Inter-assay variability was <6% for total 
PSA.
Interleukin-6 concentrations were measured using a sensitive solid phase 
enzyme linked immunosorbent assay (R & D Systems Europe Ltd, Abingdon, UK). 
The lower level of detection was 0.2 pg/1 and the intra - assay variability was less than 
6% over the sample concentration range.
C-reactive protein concentration was measured using a sensitive double 
antibody sandwich ELISA with rabbit anti-human C-reactive protein and peroxidase 
conjugated rabbit anti-human C-reactive protein. The assay was linear from 0.1 mg/1 
to 5mg/l and logarithmic thereafter. Inter-assay variation was less than 10% over the 
sample concentrations range.
Statistics
Data are presented as the median (range), and where appropriate, differences between 
control and cancer groups were examined using the Mann-Whitney U test. 
Correlations between two variables were calculated using Speannan’s rank 
correlation test. As the distribution of interleukin-6 and C-reactive protein 
concentrations were skewed, they were logarithmically transformed to illustrate their 
relationship in patients with benign prostatic disease and prostate cancer. Analysis 
was carried out using the statistics package SPSS (SPSS Inc., Chicago, Illinois USA).
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5.3 Results
One hundred and forty five patients (59 with benign prostatic disease and 86 
diagnosed with prostate cancer) were included in the study. The characteristics of the 
patients with benign prostatic disease and prostate cancer are shown in Table 5.1 and 
5.2. The majority o f patients with prostate cancer had localised or locally advanced 
disease and had a low Gleason score. Compared to patients with benign prostatic 
disease, the cancer patients had higher circulating concentrations of total PSA 
(p<0.001). There were no significant differences in circulating concentrations of 
interleukin-6 and C-reactive between patients with benign disease and prostate cancer.
The relationship between circulating concentrations of interleukin-6 and C- 
reactive protein in patients with benign prostatic disease and prostate cancer is shown 
in Figure 5.1. The coiTelation coefficients for patients with benign prostatic disease 
and prostate cancer were i*s = 0.632, p<0.001 and I's = 0.663, p<0.001 respectively.
The relationship between Gleason score, PSA, interleukin-6 and C-reactive 
protein in the patients with prostate cancer is shown in Table 5.3. With increasing 
Gleason scores there were significant increases in total PSA (p<0.05), interleukin-6 
(p<0.01) and C-reactive protein (p<0.01). There was a significant correlation 
between Gleason score and total PSA (r^  = 0.364, p=0.001), interleukin-6 (i*s = 0.311, 
p=0.004) and C-reactive protein (rg = 0.304, p=0.004). There was no significant 
association between total PSA and either interleukin-6 or C-reactive protein.
5.4 Discussion
It is recognised that diagnosis o f prostate cancer using TRUS guided biopsy cames a 
recognised false negative rate of approximately 20% (Romics, 2004). In the present
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study, however, there were no significant differences in the circulating concentrations 
of either interleukin-6 or C-reactive protein between patients with benign prostatic 
disease and those with prostate cancer. Furthermore, the relationship between 
interleukin-6 and C-reactive protein was similar in both patient groups. It is therefore 
unlikely that misclassiflcation of a small number of cancer patients would 
significantly alter the results of this study.
hi the cancer patients, there was a significant increase in both interleukin-6 
and C-reactive protein concentration with increasing tumour grade. These results are 
also consistent with previous observations that concentrations of interleukin-6 and its 
receptor are increased in patients with a Gleason score greater than 7 (Shariat et al.,
2001). This might suggest that the tumour was responsible for the increased 
production of interleukin-6. However, the increases in interleukin-6 and C-reactive 
protein were independent of total PSA.
An alternative explanation would be that the source of interleukin-6 is the host 
inflammatory cells. It is therefore of interest that recent studies have shown that a 
pronounced inflammatoiy infiltrate in the tumour was associated with poor outcome 
in patients with prostate cancer (Irani et a l, 1999; McArdle et a l, 2004).
Taken together, these observations confirm that interleukin-6 is predominantly 
responsible for the elaboration of C-reactive protein. Furtheimore, they suggest that 
interleukin-6 is produced primarily by the host rather than the tumour. Moreover, it 
may also be that interleukin-6, produced by tumour infiltrating leucocytes, stimulates 
tumour cell proliferation and promotes leucocyte recmitment as part of an autocrine 
growth factor loop (Corcoran and Costello, 2003).
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In summary, the results of the present study indicate that the relationship 
between interleukin-6 and C-reactive protein is similar in patients with benign and 
malignant prostate disease.
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Table 5.1 The characteristics of patients with benign prostatic disease and prostate 
cancer.
Benign prostatic disease Prostate cancer p-valiie
(n= 59) (n= 86)
Age (<70/ >70 yi's) 45/14 52/ 34 0.069
Stage (T1-T2/ T3-T4/ Met) 37/37/ 12
Gleason score (2-6, 7, 8-10) 46/ 24/16
Total PSA (ng/ml)* 7.0 (0.8-39) 14.6 (0.5-146) <0.001
Interleukin-6 (pg/ml)* 2.3 (0.7-12.9) 2.3 (0.8-28.1) 0.526
C-reactive protein (mg/1)* 2.0 (0.1-21.1) 1.8 (0.3-50) 0.891
Median (range)
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Figure 5.1. The relationship between circulating concentrations of inter!eukin-6 and 
C-reactive protein in patients with benign prostatic disease (O, n=59) and prostate
cancer ( • ,  n=86).
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6.1.0 An evaluation of prostate specific antigen and C-reactive protein in the 
detection of prostate cancer in a non-screened population.
6.1 Introduction
Since its introduction in the late 1980's, prostate specific antigen (PSA) remains the 
most widely used marker for the detection of prostate cancer. However, although 
PSA testing is associated with a high level o f sensitivity using conventional cut-off 
concentrations, the specificity o f the test is low since patients with benign pro static 
disease may also have elevated PSA levels.
A number of alternative approaches have been devised in an attempt to 
improve the specificity of the total PSA test, including the use of age adjusted 
reference ranges, PSA density, PSA transitional zone density and PSA velocity. 
However, none of these derived values has gained widespread acceptance in routine 
clinical practice.
Recently, the discovery of different isoforms of PSA has generated further 
interest. Circulating PSA can be divided into two main fonns, namely complexed and 
free PSA. Most circulating PSA is bound to a variety of protease inhibitors, most 
commonly alpha-1-antichymotrypsin; the proportion of free or unbound PSA is 
relatively small. Initially, there was no reliable method of measuring complexed PSA 
directly and it was therefore calculated by subtracting the unbound or “free” PSA 
from the total PSA. More recently, a method of directly measuring the 
concentrations o f complexed PSA has been developed (Allard et al, 1998). Several 
studies have suggested that the use of these PSA isofonns or their ratios provides 
greater specificity than total PSA in the detection of prostate cancer (Bangma et al, 
1997;Catalona et al, 1998; Drawer et al, 1998; Drawer et al, 2000; Okihara et al,
110
2002). Nevertheless, despite these encouraging results, there is a continuing need to 
evaluate new potential markers of malignancy.
It is therefore of interest that, as described in chapter four, the presence of a 
systemic inflammatory response, as evidenced by elevated circulating concentrations 
of C-reactive protein, is associated with poor prognosis in patients with metastatic 
prostate cancer. Furthermore, there is evidence that the systemic inflammatory 
response may play an important role in promoting disease progression. However, the 
value of measuring C-reactive protein in the diagnostic setting does not appear to 
have been assessed.
The aim of the present study was therefore 1) to evaluate the role o f PSA and 
its isoforms in the detection of prostate cancer and 2) to assess whether measurement 
of C-reactive protein concentrations was useful in discriminating between patients 
with benign disease and prostate cancer.
6.2 Patients and methods
Consecutive patients undergoing diagnostic transrectal ultrasound guided (TRUS) 
biopsy of prostate were studied prospectively. The indication for TRUS biopsy was 
either a total PSA concentration gi’eater than 4 pg/L and/or an abnonnal digital rectal 
examination. None of the patients had participated in a formal screening program. All 
patients underwent a minimum of systematic sextant biopsy.
Prior to biopsy, a blood sample was obtained and the serum stored at -20°C. 
No patient had a digital rectal examination within a two-week period prior to 
sampling. No patient was receiving treatment at the time of blood sampling.
I l l
Total and complexed PSA was measured using the Bayer AD VIA Centaur 
Assay system (Bayer PLC, Bayer House, Newbury, UK). Total and free PSA was 
measured using the Immulite 2000 Immunoassay system (Diagnostic Products 
Coiporation UK, Glyn Rhonwy, Llanberis, UK). The inter-assay variability, as 
quoted by the manufacturer was <6% and <3% for total and complexed PSA (Bayer 
assay system) with an assay sensitivity of 0.01 and 0.03pg/L respectively. The inter­
assay variability was <4% and <6% for total and free PSA (Immulite assay system) 
with an assay sensitivity o f 0.01 and 0.03 pg/L respectively.
C-reactive protein concentrations were measured by a fluorescence 
polarization immunoassay and using an Abbott TDXTM analyser and Abbott reagents 
(Abbott Laboratories, Abbott Park, Illinois, USA). The limit of the detection of the 
assay is a C-reactive protein concentration lower than 5mg/L. The coefficient of 
variation, over the range of measurement, was less than 5 per cent, as established by 
routine quality control procedures. Based on previous work a C-reactive protein 
concentration of greater than lOmg/L was considered to indicate the presence of a 
systemic inflammatory response.
The study was approved by the local ethics committee.
Statistics
Data are presented as median and range. Where appropriate comparison between 
unpaired data was carried out using the Mann-Whitney U-test. Agreement between 
the two methods of measuring total PSA was assessed using a paired sample T-test. 
Correlations between two variables were calculated using Speai*man's rank 
correlation test.
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Receiver operating characteristics (ROC) cui*ves were generated by plotting the 
sensitivity versus (1-specificity) as previously described (Babian et al, 1996). The 
area under the ROC cuiwe was calculated for total PSA, complexed PSA, free PSA, 
complexed-to-total and free-to-total PSA. Analysis was performed using SPSS 
software (SPSS hic, Chicago, Illinois, USA).
6.3 Results
One hundred and seventy one men were included in the study. O f these, 103 (60%) 
were found to have histologically proven prostate cancer, 8 (5%) had prostatic 
intraepithélial neoplasia and the remaining 60 (35%) had benign prostatic disease.
For the purpose of this study, patients with prostatic intraepithélial neoplasia were 
included in the non-cancer group. The median ages in the benign and cancer groups 
were 66 (range 45-79) and 69 (range 46-88, p<0.01) respectively.
The results of the total, complexed and free PSA assays are shown in table 6.1. 
When the two methods of measuring total PSA were compared, the difference 
between the values obtained using the two assays was shown to vary in proportion to 
the PSA concentration. Using a paired sample T-test the values obtained using the 
Immulite 2000 assay were significantly higher by a mean of 12.5% (95% Cl 10%- 
15%, p<0.001) than the values obtained with the Bayer assay.
There was a significant positive coiTelation between the values of total PSA 
and complexed (r=0.978, p<0.001) and free PSA (r=0.807, p<0.001). There was also 
a significant negative correlation between total PSA and the free/total ratio (i^ -0.346,
p<0.001).
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Total PSA, measured using both techniques, was significantly higher in the 
patients with histologically confirmed prostate cancer compared to patients with 
benign disease (p<0.001; table 6.1). There were also significant differences in 
complexed PSA (p<0.001), complexed/total PSA (p-0.033) and free/total PSA 
(p<0.001) between patients with prostate cancer and those with benign disease.
There was no significant difference in C-reactive protein concentrations 
between patients with benign and malignant prostate disease.
ROC analysis showed that, when all patients were examined, the areas under 
the ROC curves for total and complexed PSA, and the free/total ratio were similar 
(Figure 6.1, table 6.1).
Using the conventional diagnostic cut-off of 4 pg/L, as measured by the Bayer 
assay, the sensitivity and specificity of total PSA was 90% and 24% respectively 
(table 6.2). Fixing the sensitivity of the other assays at 90%, the corresponding 
specificities for complexed PSA and the free/total PSA ratio were 24% and 21% 
respectively.
Seventy-seven patients had total PSA concentrations between 2 and 10 pg/L 
as measured using the Bayer assay (table 6.3). ROC curve analysis showed that total 
and complexed PSA failed to discriminate between benign and malignant disease. In 
contrast, the areas under the curve were greater for the complexed to total ( p=0.057) 
and the free to total ( p=0.033) ratios (Figure 6.2).
Using the conventional cut-off of 4pg/L, the specificities for the complexed to 
total and free to total ratios were 40% and 42% respectively compared with 
approximately 20% for total and complexed PSA (table 6.4).
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6.4 Discussion
The use of prostate specific antigen to detect prostate cancer is well established. 
However, although PSA has been shown to be a highly sensitive method of detecting 
the presence of prostate cancer, concern has been expressed about the relative lack of 
specificity, particularly in screened populations where low specificity results in a high 
proportion of umiecessary biopsies (Bangma et al, 1997;Catalona et al, 1998; Brawer 
et al, 1998; Brawer et al, 2000; Okihara et al, 2002). As a result, there is increasing 
interest in the use of the complexed and fi-ee iso forms of PSA as a potential method of 
increasing the ability to discriminate between those patients with benign disease and 
those with prostate cancer.
Most of the infoiTnation about free and complexed PSA has been derived from 
retrospective studies based on asymptomatic screened populations in North America. 
For example, Bangma and his co-workers (1997) found that the fi-ee to total PSA ratio 
was more specific than total PSA, but only in patients with a total PSA greater than 7 
pg/L. Subsequently, Catalona and his colleagues (1998) reported that the use of the 
free-to-total PSA ratio increased specificity between 4-10 pg/L, while maintaining 
sensitivity. Brawer and his co-workers (1998) initially reported that complexed PSA 
performed better than either total PSA or the free to total PSA ratio. Brawer and his 
colleagues (2000) subsequently reported that the specificity of complexed PSA was 
equivalent to that of the free-to-total PSA. In contrast, Okihara and his co-workers 
(2002) reported that complexed PSA was equivalent to total PSA and that fi-ee-to-total 
PSA was superior to both. Some of these apparent contradictions might be explained 
by the retrospective nature o f some of these studies, the use of non-consecutive
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subjects and the use of different total PSA concentrations to define the patient 
population of interest.
The clinical value o f complexed and free PSA, and their ratios, especially as it 
pertains to routine clinical practice in an unscreened population in the UK remains 
uncertain. Some studies have failed to show an advantage in the use o f the free to 
total PSA ratio compared to total PSA (Masters et al, 1998; Klingler et al, 1998); 
however, the numbers studied were small. In contrast, Jung and his colleagues (2000) 
reported that, in patients with total PSA concentrations between 2 and 10 pg/L, 
complexed PSA was equivalent to total PSA, but that specificity increased 
substantially if either the complexed-to-total or free-to-total ratio was used.
The results of the present study, in an unscreened population show that, 
overall, there were significant differences in the total and complexed PSA 
concentrations, the complexed to total and free-to-total PSA ratios between patients 
with prostate cancer and those with benign disease. Indeed, ROC cuiwe analysis 
showed that the areas under the cui*ves for total and complexed PSA, and the free to 
total PSA ratio were similar. Using the conventional cut-off of 4 pg/L for total PSA, 
the corresponding specificities for total PSA, complexed PSA and the free-total PSA 
ratio were also similar.
Confining the analysis to the 77 patients with total PSA concentrations 
between 2 pg/L and 10 pg/L, ROC cuiwe analysis demonstrated that the complexed to 
total and the fr'ee to total ratios were better than total PSA in discriminating between 
patients with benign and malignant disease. These results are therefore similar to 
those reported by Jung and his co-workers.
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In contrast the results of the present study indicated that C-reactive protein 
concentrations were not of value in differentiating between patients with benign and 
malignant disease. The failure of C-reactive protein to differentiate between benign 
and malignant disease may be due to the fact the presence of a systemic inflammatory 
response in patients with symptomatic prostatic disease may reflect either the 
presence of cancer or other disease processes such as urinary tract infection. 
Fiirthennore, whereas PSA is produced directly by the tumour, C-reactive protein is a 
non-specific host response. It is therefore not surprising that PSA had greater 
discriminatory power than C-reactive protein.
In summary, the results of the present study, in a non-screened population, 
show that, overall, the use of the PSA isoforms and their ratios did not provide 
additional discriminatory power. However, in a subset of patients with total PSA 
concentrations between 2 and 10 pg/L, the free to total PSA ratio was superior to total 
PSA in discriminating between patients with benign and malignant disease.
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Table 6.1. The relationship between total, free and complexed PSA in patients with
benign disease or prostate cancer (entire cohort).
Benign Cancer Ai'ea under ROC P value
(n=6 8 ) (n=103) curve (95%CI)
Total PSA- (Bayer) 6.9 (0.4-39.0) 12.7 (0.5-146.0) 0.698 (0.619-0.777) <0.001
(pg/L)
Complexed PSA 5.0 (0.3-26.7) 10.3 (0.3-80.0) 0.707 (0.629-0.784) <0.001
(pg/L)
Complexed/ total PSA 74.5 (7.5-92.0) 78.6 (27.0-97.0) 0.597 (0.510-0.683) 0.033
Total PSA- (hnmulite) 8.1 (0.4-39.6) 14.8 (0.3-264.0) 0.710 (0.632-0.788) <0.001
(pg/L)
Free PSA 1.1 (0.1-6.7) 1.3 (0.1-85.5) 0.581 (0.494-0.669) 0.072
(pg/L)
Free/ total PSA 14.3 (4.0-52.5) 9.3 (3.0-32.4) 0.718 (0.642-0.795) <0.001
Median (range)
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Table 6.2. Relative specificity of total, free and complexed PSA at 90% sensitivity
Cut-off Sensitivity specificity
Total PSA (Bayer) 4pg/L 90% 24%
Complexed PSA 2.9pg/L 90% 24%
Complexed/total ratio 62.5% 90% 1 0 %
Total PSA- (Immulite) 4.8pg/L 90% 27%
Free/total ratio 2 0 % 90% 2 1 %
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Table 6.3. The relationship between total, free and complexed PSA in patients with
benign disease or prostate cancer (within a total PSA range of 2-10 pg/L)
Benign
(n=40)
Cancer
(n=37)
Area under ROC P value 
cuiwe (95% Cl)
Total PSA- (Bayer) 6.1 (2.1-10.0) 6 .6  (2.2-10.0) 0.522 (0.391-0.653) 0.740
(pg/L)
Complexed PSA 4.6 (1.5-7.9) 4.9(1.5-8.4) 0.548 (0.418-0.679) 0.466
(pg/L)
Complexed/total PSA 74.5 (7.5-91.0) 81.0 (50.9-96.0) 0.626 (0.501-0.752) 0.057
Total PSA- (hnmulite) 6 .8  (2.3-11.1) 7.2 (2.3-12.5) 0.544 (0.412-0.675) 0.511
(pg/L)
14.1 (5.4-40.6) 11.9 (3.0-27.8) 0.642 (0.517-0.766) 0.033Free/total PSA
Median (range)
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Table 6.4. Relative specificity of total, free and complexed PSA at 80% sensitivity.
Cut-off Sensitivity specificity
Total PSA (Bayer) 4pg/L 80% 20%
Complexed PSA 3.1 pg/L 80% 20%
Complexed/ total ratio 72.3% 80% 40%
Total PSA- (Immulite) 4.9pg/L 80% 25%
Free/total ratio 16.5% 80% 42%
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Figure 6.1. ROC curves for entire patient cohort (n= 171)
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Figure 6.2. ROC curves for patient cohort with total PSA concentrations 2-lOpg/L 
(n= 77).
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7.0.1 Discussion
It has long been recognised that disease progression in cancer patients is not solely 
determined by the characteristics of the tumour but also by the host response 
(Balkwill and Mantovani, 2001). Indeed there is increasing evidence that both local 
and systemic inflammatory responses play an important role in the progression of a 
variety of common solid tumours (Coussens and Werb, 2002).
For example, in patients with colorectal cancer, there is good evidence that the 
presence o f a pronounced lymphocytic infiltration within the tumour is associated 
with improved survival (Jass et al, 1987; Ropponen et al, 1997; Nielsen et al, 1999). 
Conversely, the presence of a systemic inflammatory response, as evidenced by the 
presence of an elevated circulating C-reactive protein concentration, is associated 
with poor prognosis (Nielsen et al., 2000; McMillan et al., 2003).
The relationship between lymphocytic infiltration and survival in patients with 
urological cancers is unclear. At the time that this work was carried out, only two 
studies had evaluated the impact of tumour lymphocyte infiltration on outcome in 
patients with prostate cancer. However, the conclusions reached by these studies 
appeared to be contradictory. Furthermore, the relationship between specific 
lymphocyte subset infiltration and survival does not appear to have been assessed in 
these patients.
In chapter 3, the relationship between lymphocytic subset infiltration and 
sui-vival was examined. In a cohort of 80 patients with untreated prostate cancer, it 
was shown that the presence of a profuse CD4+ but not CD8+ lymphocytic 
infiltration within the tumour bed was associated with a poor prognosis, independent 
of stage, grade and subsequent treatment. This study therefore provides evidence that
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the presence of a local inflammatory response is an important factor in determining 
the prognosis in patients with prostate cancer.
At presentation, there are a number of tumour based factors, which can be 
used to predict the extent of disease and therefore suiwival in patients with prostate 
cancer. These include clinical stage, tumour grade and circulating concentrations of 
PSA. However, predicting prognosis duiing the follow-up period is more difficult, 
since treatment for prostate cancer may suppress circulating PSA concentrations to 
varying degrees.
Few studies have examined the value of an elevated circulating C - reactive 
protein concentration, as a prognostic factor in patients with prostate cancer. It is 
therefore of interest that Trautner and co-workers (1980) reported that, in a 
heterogeneous group o f patients, a rise in circulating C-reactive protein concentrations 
was associated with disease progression even when patients were receiving honnone 
therapy.
In chapter 4, the impact o f an elevated circulating C-reactive protein 
concentration on survival was assessed in a cohort of 62 patients receiving hormone 
treatment for metastatic prostate cancer. This study showed that in patients with 
metastatic prostate cancer, the presence o f a systemic inflammatory response during 
the follow-up period may predict poor outcome, independent of PSA.
The mechanism by which a systemic inflammatory response might impact on 
cancer-specific survival is not clear. There is evidence to suggest that interleukin-6 , 
which is largely responsible for the production of C-reactive protein can be produced 
by prostatic tumours. Furtheimore, increased circulating concentrations of 
interleukin-6  have been shown to be associated with reduced survival in patients with 
prostate cancer. Interleukin-6  has also been shown to act as an autocrine growth
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factor (Okamoto et al, 1997) and to inhibit apoptosis in prostate cancer (Chung et al, 
2000).
A number of factors appear to mediate the increased production of C-reactive 
protein. In injury, the pro-inflammatory cytokines, interleukin-1, TNF-alpha and 
interleukin-6  in particular, have been shown to stimulate the production of C-reactive 
protein (Gabay and Kushner, 1999). In cancer, the factors which detennine 
circulating concentrations of C-reactive protein are less clear since studies in cell lines 
and animal tumour models have demonstrated that a number of factors stimulate C- 
reactive protein production. It might therefore be anticipated that the relationship 
between C-reactive protein and IL-6  would be different in patients with prostate 
cancer from those with benign disease.
In chapter 5, the relationship between circulating concentrations of C-reactive 
protein and IL-6  was assessed in a cohort of 145 patients (59 with benign disease and 
8 6  with prostate cancer). Compared to patients with benign pro static disease, the 
cancer patients had higher circulating concentrations of total PSA. There were no 
significant differences in circulating concentrations of interleukin- 6  and C-reactive 
between patients with benign disease and prostate cancer. Moreover, the relationship 
between C-reactive protein and its coiTesponding pro-inflammatory cytokine 
interleukin-6  was found to be similar in both benign and malignant disease. Taken 
together this might suggest that interleukin-6  is primarily produced by the host 
inflammatory cells, possibly by tumour infiltrating leucocytes.
Given that we have shown that the inflammatory response is important in 
disease progression in patients with prostate cancer, we postulated that measurement 
of circulating C-reactive protein concentrations might prove a useful tool in helping to 
diagnose patients with prostate cancer. The process of investigation and diagnosis of
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patients suspected of having prostate cancer is currently problematical since total PSA 
which is cuiTently used to identify patients at risk of having prostate cancer lacks 
specificity. This inherent weakness means that a large proportion of patients cuiTently 
subjected to prostatic biopsy have benign disease.
In chapter 6 , we examined the ability of C-reactive protein , total PSA and 
PSA isofoims to discriminate between benign disease and prostate cancer in a cohort 
of 171 patients attending a number of hospitals for a diagnostic TRUS biopsy. In a 
subset of patients with total PSA concentrations between 2 and 10 pg/L, the free to 
total PSA isofomi ratio was found to be superior to total PSA in discriminating 
between patients with benign and malignant disease. There was no significant 
difference in circulating C-reactive protein concentrations between patients with 
benign and malignant prostate disease and therefore it is unlikely to be useful in the 
discrimination between benign and malignant disease.
The mechanisms by which the inflammatory response might influence disease 
progression and impact on cancer-specific survival are not clear. However, 
interleukin-6 , which is largely responsible for the production of C-reactive protein, 
has also been shown to act as an autocrine growth factor and to inhibit apoptosis in 
prostate cancer. It is also not clear why the presence of an increase in CD4+ T- 
lymphocyte infiltrate would be associated with poor suiwival in patients with prostate 
cancer. It may be that many of the T-lymphocytes found in tumour beds are inactive 
and therefore do not contribute to effective anti-tumoral immunity (Naoe et al., 2002).
The relationship between the local and systemic inflammatory responses is not 
clear. However, it may be that both the local and systemic inflammatory responses 
impact on disease progression and survival through the cyclooxygenase pathway. For 
example, it is thought that the COX enzymes may contribute directly to the
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carcinogenic process through the production of oxygen fi-ee radicals and 
malondialdehyde which are known to stimulate mutagenic changes in DNA 
(Kirschenbaum et al, 2001).
There is also evidence to suggest that the COX enzymes may also be 
implicated in promoting tumour growth and dissemination. For example, there is 
evidence to suggest that prostaglandins may have a role in protecting tumour cells 
fiom undergoing apoptosis and thereby encourage tumour growth (Liu XH et al,
1998). Furtheimore, COX-2 expression has been strongly associated with expression 
of vascular endothelial growth factor which is known to promote neovascularisation 
and thus facilitate tumour growth and spread of tumour cells (Timoshenko et al,
2006). It has also been postulated that the production of prostaglandins may result in 
apoptosis of immune cells such as natural killer cells (Myers et al, 2001). This in turn 
may allow tumour cells to gi'ow and disseminate whilst escaping fi"om immune 
surveillance mechanisms. It is therefore of interest that recent studies have shown 
that COX-2 expression can be induced by both tissue infiltration by T-lymphocytes 
and pro-inflammatory cytokines such as IL-6  (Wang et al, 2005).
The results of the above studies suggest that tumour progi'ession and the 
inflammatory response are intimately linked in patients with prostate cancer. 
Specifically, these studies have demonstrated that both the presence of a pronounced 
lymphocytic infiltration within the primary tumour bed and the presence of a systemic 
inflammatory response are associated with poor outcome in patients with prostate 
cancer. This raises the prospect that it might be possible to delay tumour progi'ession 
and improve survival by modifying the inflammatory response through the use of 
NSAIDs. This might be of particular importance in some patients with advanced 
disease, for example those patients with hormone-escaped prostate cancer and
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evidence of a systemic inflammatory response, where treatment options are currently 
limited.
Moreover, it is well recognised that a high proportion o f patients with 
advanced prostate cancer develop the loss o f weight, reduced appetite and reduced 
perfoimance status characteristic of cancer cachexia syndrome. These symptoms 
lead to a significant reduction in quality of life and are cuiTently resistant to 
conventional treatment. It is therefore of great interest that previous studies have 
shown that NSAIDs can reverse the above changes in gastro-intestinal cancer patients 
with weight loss (McMillan et al., 1999; Lundholm et al., 2004). To date, no studies 
have evaluated the role o f NSAIDs in the management of patients with prostate 
cancer and cachexia.
It has long been recognised that inflammation contributes to carcinogensis in 
many common solid tumours. There is also evidence to suggest that modification of 
the inflammatory response may reduce the risk of developing some cancers. At 
present, it is not clear whether inflammation precedes the development of prostate 
cancer. However, a recent meta-analysis reported that the use of aspirin reduced the 
risk of developing prostate cancer (Malunud et al, 2004). These studies suggest that 
there may be a further role for NSAIDs as chemopreventative agents.
In summary, the results of the present studies are consistent with the 
hypothesis that the host inflammatory response is associated with disease progression 
in patients with prostate cancer.
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Areas of ongoing research
This work presented in thesis has led to a number of avenues of research;
How is T-lymphocytic infiltration regulated in prostate cancer? We are 
cuiTently examining the relationship between COX-2 expression and lymphocytic 
infiltration in patients undergoing radical local treatment for histologically proven 
prostate cancer.
What is the basis of the association between an elevated C-reactive protein 
concentration and poor cancer specific suiwival in patients with metastatic prostate 
cancer? We are currently examining the relationship between the presence of a 
systemic inflammatory response, as evidenced by an elevated circulating C-reactive 
protein concentration, and lean body mass (a primary determinant of survival) as 
measured by total body potassium in patients with metastatic prostate cancer.
What is the cytokine profile associated with the systemic inflammatory 
response in patients metastatic prostate cancer? We are cun'ently examining the effect 
of the administration of a NS AID (Ibuprofen) on the plasma cytokine and acute phase 
protein profile of patients with metastatic prostate cancer.
We have obtained ethics approval and are cun'ently recmiting patients for the 
above studies.
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